Lupus Nephritis

Complex MONDO:0005556 Pathograph 10 Show in embeddings browser

Lupus nephritis is an immune-complex glomerulonephritis that is one of the most severe organ manifestations of systemic lupus erythematosus (SLE). Anti-dsDNA and anti-chromatin (anti-nucleosome) autoantibodies form immune complexes that deposit in — or bind in situ to nucleosomes/DNA within — the glomerulus, driving complement activation, Fc-receptor and Toll-like-receptor engagement, and inflammatory tissue injury. The clinicopathologic spectrum is graded by the ISN/RPS classification from mild mesangial involvement (class I/II) through focal and diffuse proliferative disease (class III/IV) and membranous disease (class V) to advanced sclerosis (class VI), and manifests clinically with proteinuria, an active urinary sediment, hypertension, and progression to chronic kidney disease or end-stage kidney disease.

Ask OpenScientist

Ask a research question about Lupus Nephritis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
9
Pathophys.
5
Phenotypes
2
Hypotheses
1
Gaps
10
Pathograph
10
Medical Actions
6
Datasets
1
Deep Research
🏷

Classifications

Harrison's Part
KIDNEY URINARY TRACT IMMUNE RHEUMATOLOGIC
👪

Inheritance

1
Polygenic / multifactorial susceptibility HP:0010982
Lupus nephritis has no simple Mendelian inheritance. Renal susceptibility within SLE is multifactorial, with contributions from complement-pathway genes, Fc-gamma receptor (FcgR) gene variants and copy-number changes, and HLA and interferon-axis loci, modified by sex and ancestry. Rare early-complement-component (e.g. C1q) deficiency is a strong monogenic risk factor for lupus.
Polygenic inheritance
Show evidence (1 reference)
PMID:22192660 SUPPORT Human Clinical
"Similarly, reports of associations of FcγR genetic changes with nephritis appear linked to specific ethnicities"
Supports a polygenic, ancestry-modified genetic contribution (FcgR variants) to lupus nephritis susceptibility.
◈

Mechanistic Hypotheses

2
Unidirectional Immune-Complex Injury Model
unidirectional_immune_injury_model CANONICAL
Evidence balance 2 support
The classical account treats the kidney as a passive target of systemic autoimmunity: autoreactive B cells and plasma cells generate anti-dsDNA and anti-chromatin antibodies, the resulting immune complexes deposit in — or bind in situ within — the glomerulus, and complement, Fc-receptor, and Toll-like-receptor engagement drive inflammatory glomerular and tubulointerstitial injury. Causal flow runs in one direction, from systemic autoimmunity to renal tissue damage, and this model underwrites systemic immunosuppression as the therapeutic strategy.
Pathograph links
Autoantibody Production and Immune Complex Formation -> Glomerular Immune Complex Deposition DIRECT Pathogenic anti-dsDNA/anti-chromatin antibodies deposit as immune complexes in the glomerulus.
Glomerular Immune Complex Deposition -> Complement Activation and Glomerular Inflammation DIRECT Deposited immune complexes co-stimulate Fc receptors and endosomal TLRs and activate complement.
Complement Activation and Glomerular Inflammation -> Glomerular and Tubulointerstitial Injury DIRECT Complement activation and inflammatory infiltration are deleterious, driving glomerular and tubular tissue injury.
Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu -> Glomerular and Tubulointerstitial Injury DIRECT The intrarenal infiltrate and cytokine milieu are in part directly responsible for the tissue damage observed in lupus nephritis.
Show evidence (2 references)
PMID:22192660 SUPPORT Human Clinical
"Pathogenic anti-dsDNA antibodies deposit as immune complexes"
Supports the autoantibody-to-deposition step that opens the unidirectional chain.
PMID:39120952 SUPPORT Other
"It is now increasingly appreciated that LN is not due to unidirectional immune cell activation with subsequent kidney damage."
This review does not dispute that immune-complex-driven activation causes renal injury, but holds the strictly unidirectional framing to be an incomplete account of lupus nephritis — hence PARTIAL rather than SUPPORT for the model as a whole.
Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
bidirectional_kidney_immune_crosstalk EMERGING
Evidence balance 1 support
An extension in which the kidney is an active participant rather than a passive target. The renal biochemical niche (low oxygen tension and hypertonicity) together with intrinsic renal cell types — which can present antigen and produce cytokines — shapes the recruitment, survival, differentiation, and activation of the intrarenal immune infiltrate; those conditioned immune cells in turn modify kidney cell function, closing a self-amplifying loop. The model does not replace the immune-complex cascade; it adds a reciprocal arm downstream of it, and it predicts that kidney-targeted rather than systemic intervention could interrupt the loop.
Status is EMERGING rather than CANONICAL because the supporting citation is a narrative review synthesizing largely mechanistic and model-system work; the reciprocal arm has not been shown to drive human renal outcomes independently of the immune-complex cascade.
Pathograph links
Complement Activation and Glomerular Inflammation -> Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu DIRECT Complement- and Fc-receptor-driven glomerular inflammation recruits leukocytes into the kidney, establishing the intrarenal immune infiltrate and cytokine milieu that characterizes the lupus kidney.
Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu -> Intrinsic Renal Cell Antigen Presentation and Cytokine Production DIRECT Infiltrating immune cells and their cytokines act on intrinsic renal cells, engaging the renal-cell arm of the reciprocal loop. Note this edge deliberately targets the induced renal-cell activity, not the renal biochemical niche, which is constitutive rather than immune-induced. Evidence caveat: the cited abstract states a general effect on intrinsic renal cells ("affects intrinsic renal cells") and describes antigen presentation and cytokine production in the renal-to-immune direction; that the infiltrate specifically induces those two pathways is a reasonable inference from the review's framing rather than a sentence it states, so the specificity of this edge is weaker than its direction.
Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu -> Glomerular and Tubulointerstitial Injury DIRECT The intrarenal infiltrate and cytokine milieu are in part directly responsible for the tissue damage observed in lupus nephritis.
Renal Biochemical Niche (Low Oxygen Tension and Hypertonicity) -> Intrarenal Immune Cell Conditioning and Activation DIRECT The renal biochemical niche acts on the immune cells that enter it, shaping their behaviour within the kidney.
Intrinsic Renal Cell Antigen Presentation and Cytokine Production -> Intrarenal Immune Cell Conditioning and Activation DIRECT Antigen presentation and cytokine production by intrinsic renal cells act on the intrarenal immune cells, the second input to their conditioning.
Intrarenal Immune Cell Conditioning and Activation -> Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu DIRECT Feedback arm: kidney-conditioned recruitment, survival, and differentiation amplify and sustain the local infiltrate. This edge closes the loop that distinguishes the bidirectional model from the classical unidirectional cascade.
Intrarenal Immune Cell Conditioning and Activation -> Altered Intrinsic Renal Cell Function DIRECT The second half of the review's reciprocal sentence: the conditioned immune cells in turn modify the function of the kidney's own cells.
Altered Intrinsic Renal Cell Function -> Glomerular and Tubulointerstitial Injury DIRECT Immune-cell-driven alteration of intrinsic renal cell function is part of what produces the tissue damage seen in lupus nephritis.
Show evidence (1 reference)
PMID:39120952 SUPPORT Other
"the kidney microenvironment influences the recruitment, survival, differentiation, and activation of immune cells, which, in turn, modify kidney cell function"
States the reciprocal kidney-to-immune-cell and immune-cell-to-kidney arms that define this model.
?

Discussions and Knowledge Gaps

1
Can the intrarenal kidney-immune crosstalk loop be interrupted by kidney-targeted therapy without systemic immunosuppression, and does doing so improve renal outcomes relative to the current systemic regimens?
KNOWLEDGE GAP OPEN gap_kidney_targeted_ln_therapy
Attached to
pathophysiology#Renal Biochemical Niche (Low Oxygen Tension and Hypertonicity) pathophysiology#Intrinsic Renal Cell Antigen Presentation and Cytokine Production pathophysiology#Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu
Every treatment currently curated on this entry — mycophenolate/cyclophosphamide induction, corticosteroids, belimumab, voclosporin, obinutuzumab, rituximab, azathioprine — acts systemically, which follows from the unidirectional model in which the kidney is a passive target. If the reciprocal arm is a genuine driver, the loop is in principle interruptible at renal-restricted nodes (the hypoxic and hypertonic niche, renal antigen presentation, renal cytokine production) that systemic immunosuppression does not specifically address. The gap is that no kidney-targeted agent acting on these nodes has been shown to change renal outcomes in patients, so the therapeutic claim remains a prediction of the model rather than a curated treatment.
Proposed experiments
Renal-restricted target engagement with paired kidney biopsy readouts
exp_ln_renal_restricted_target_engagement
Test an agent directed at a renal-restricted node of the loop (for example renal antigen presentation or the hypoxia/hypertonicity response) using paired pre- and post-treatment kidney biopsies, scoring change in the intrarenal immune infiltrate and local cytokine milieu alongside proteinuric response, and comparing against a systemically immunosuppressed control arm to establish whether renal-compartment engagement is separable from systemic effect.
Show evidence (1 reference)
PMID:39120952 SUPPORT Other
"An understanding of these mechanisms can lead to the design of more kidney-targeted treatments and the avoidance of systemic immunosuppressive effects and may represent the next frontier of LN therapies."
Frames kidney-targeted therapy as a prospective consequence of these mechanisms ("can lead to", "may represent"), i.e. an open question rather than a demonstrated therapeutic result.
⚙

Pathophysiology

9
Autoantibody Production and Immune Complex Formation
Failure of B-cell tolerance in SLE generates anti-dsDNA and anti-chromatin (anti-nucleosome) autoantibodies from autoreactive B cells and plasma cells. These antibodies to DNA/nucleosomes are the autoantibody species most closely linked to the development of nephritis and form circulating and in-situ immune complexes.
Unidirectional Immune-Complex Injury Model
B cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology. plasma cell CL:0000786 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves plasma cell (CL:0000786). CL:0000786 is a cell type from the Cell Ontology.
Immunoglobulin production GO:0002377 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Immunoglobulin production (GO:0002377). GO:0002377 is a biological process from the Gene Ontology. ↑ INCREASED Humoral immune response mediated by circulating immunoglobulin GO:0002455 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal Humoral immune response mediated by circulating immunoglobulin (GO:0002455). GO:0002455 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Glomerular Immune Complex Deposition Pathogenic anti-dsDNA/anti-chromatin antibodies deposit as immune complexes in the glomerulus. Unidirectional Immune-Complex Injury Model
Show evidence (2 references)
PMID:22192660 SUPPORT Human Clinical
"Antibodies to dsDNA/nucleosomes are most closely linked with development of nephritis"
Identifies anti-dsDNA/nucleosome antibodies as the autoantibody species most associated with lupus nephritis.
PMID:42413709 SUPPORT Other
"anti-DNA antibody structures and anti-chromatin antibodies; their origins, and their impact on operational molecular and cellular processes accounting for lupus nephritis"
Situates chromatin-directed autoantibodies at the center of the molecular and cellular processes producing lupus nephritis.
Glomerular Immune Complex Deposition
Immune complexes accumulate in the glomerulus both by deposition of circulating complexes and by in-situ binding of anti-dsDNA/chromatin antibodies to nucleosomes and DNA present in the glomerular matrix, engaging mesangial cells, glomerular endothelium, and podocytes across the mesangial, subendothelial, and subepithelial compartments that define the ISN/RPS histologic classes.
Unidirectional Immune-Complex Injury Model
glomerular mesangial cell CL:1000742 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glomerular mesangial cell (CL:1000742). CL:1000742 is a cell type from the Cell Ontology. glomerular capillary endothelial cell CL:1001005 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glomerular capillary endothelial cell (CL:1001005). CL:1001005 is a cell type from the Cell Ontology. podocyte CL:0000653 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves podocyte (CL:0000653). CL:0000653 is a cell type from the Cell Ontology.
Downstream
Complement Activation and Glomerular Inflammation Deposited immune complexes co-stimulate Fc receptors and endosomal TLRs and activate complement. Unidirectional Immune-Complex Injury Model
Show evidence (1 reference)
PMID:22192660 SUPPORT Human Clinical
"anti-dsDNA/chromatin antibodies binding to nucleosomes/DNA present in the glomerular matrix, as the most compelling"
Supports the in-situ binding mechanism of glomerular immune-complex formation.
Complement Activation and Glomerular Inflammation
Glomerular immune complexes activate the complement cascade — deposition of complement proteins in glomeruli is a hallmark of lupus nephritis — and recruit macrophages and other leukocytes, producing an inflammatory glomerular microenvironment. Concurrent anti-C1q antibodies accelerate renal disease.
Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model Unidirectional Immune-Complex Injury Model
macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
Complement activation, classical pathway GO:0006958 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Complement activation, classical pathway (GO:0006958). GO:0006958 is a biological process from the Gene Ontology. ↑ INCREASED Inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Glomerular and Tubulointerstitial Injury Complement activation and inflammatory infiltration are deleterious, driving glomerular and tubular tissue injury. Unidirectional Immune-Complex Injury Model
Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu Complement- and Fc-receptor-driven glomerular inflammation recruits leukocytes into the kidney, establishing the intrarenal immune infiltrate and cytokine milieu that characterizes the lupus kidney. Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
Show evidence (2 references)
PMID:22192660 SUPPORT Human Clinical
"Deposition of complement proteins in glomeruli is a key feature of lupus nephritis."
Establishes glomerular complement deposition as a defining feature of lupus nephritis.
PMID:22192660 SUPPORT Human Clinical
"When anti-C1q antibodies are present along with anti-dsDNA antibodies, development of renal disease is accelerated"
Supports anti-C1q antibodies as an accelerant of complement-driven renal disease.
Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu
Downstream of complement and Fc-receptor activation, the lupus kidney accumulates a substantial infiltrate of T cells, macrophages, and other leukocytes together with a proinflammatory cytokine milieu. This intrarenal compartment is not merely a bystander readout of systemic autoimmunity: the infiltrating cells and the cytokines they produce act directly on intrinsic renal cells, and are in part responsible for the tissue damage seen in lupus nephritis.
Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model Unidirectional Immune-Complex Injury Model
T cell CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology. macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
Leukocyte migration into the kidney GO:0050900 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Leukocyte migration into the kidney, annotated with leukocyte migration (GO:0050900). GO:0050900 is a biological process from the Gene Ontology. ↑ INCREASED Proinflammatory cytokine production GO:0001816 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Proinflammatory cytokine production, annotated with cytokine production (GO:0001816). GO:0001816 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Intrinsic Renal Cell Antigen Presentation and Cytokine Production Infiltrating immune cells and their cytokines act on intrinsic renal cells, engaging the renal-cell arm of the reciprocal loop. Note this edge deliberately targets the induced renal-cell activity, not the renal biochemical niche, which is constitutive rather than immune-induced. Evidence caveat: the cited abstract states a general effect on intrinsic renal cells ("affects intrinsic renal cells") and describes antigen presentation and cytokine production in the renal-to-immune direction; that the infiltrate specifically induces those two pathways is a reasonable inference from the review's framing rather than a sentence it states, so the specificity of this edge is weaker than its direction. Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
Glomerular and Tubulointerstitial Injury The intrarenal infiltrate and cytokine milieu are in part directly responsible for the tissue damage observed in lupus nephritis. Unidirectional Immune-Complex Injury Model Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
Show evidence (1 reference)
PMID:39120952 SUPPORT Other
"The kidney in LN is characterized by a significant immune infiltrate and proinflammatory cytokine milieu"
Supports the intrarenal immune infiltrate and cytokine milieu as a defining feature of the lupus kidney.
Renal Biochemical Niche (Low Oxygen Tension and Hypertonicity)
The kidney's distinctive biochemical environment — the low oxygen tension of the corticomedullary gradient and the hypertonicity of the medullary interstitium — is a constitutive feature of normal renal physiology, not a state induced by lupus. It is modelled here as an initiating, contextual node because it is the pre-existing environment that infiltrating immune cells arrive into, and it shapes how those cells behave once they are there. It therefore carries no incoming edge from the immune infiltrate.
Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
kidney epithelial cell CL:0002518 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves kidney epithelial cell (CL:0002518). CL:0002518 is a cell type from the Cell Ontology. kidney tubule cell CL:1000507 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves kidney tubule cell (CL:1000507). CL:1000507 is a cell type from the Cell Ontology.
Renal cellular response to low oxygen tension GO:0071456 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Renal cellular response to low oxygen tension, annotated with cellular response to hypoxia (GO:0071456). GO:0071456 is a biological process from the Gene Ontology. Response to medullary hypertonicity GO:0006972 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Response to medullary hypertonicity, annotated with hyperosmotic response (GO:0006972). GO:0006972 is a biological process from the Gene Ontology.
Downstream
Intrarenal Immune Cell Conditioning and Activation The renal biochemical niche acts on the immune cells that enter it, shaping their behaviour within the kidney. Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
Show evidence (1 reference)
PMID:39120952 SUPPORT Other
"low oxygen tension and hypertonicity) and unique kidney cell types affect the intrarenal immune cells in LN"
Identifies low oxygen tension and hypertonicity as the biochemical environment of the kidney in this model.
Intrinsic Renal Cell Antigen Presentation and Cytokine Production
Intrinsic renal cells are not passive bystanders to the infiltrate. They interact with intrarenal immune cells through defined pathways — notably antigen presentation and cytokine production — and so participate directly in local immune regulation. Unlike the biochemical niche, this activity is induced by, and downstream of, the intrarenal immune infiltrate.
Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
kidney epithelial cell CL:0002518 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves kidney epithelial cell (CL:0002518). CL:0002518 is a cell type from the Cell Ontology. kidney tubule cell CL:1000507 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves kidney tubule cell (CL:1000507). CL:1000507 is a cell type from the Cell Ontology. glomerular mesangial cell CL:1000742 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glomerular mesangial cell (CL:1000742). CL:1000742 is a cell type from the Cell Ontology. podocyte CL:0000653 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves podocyte (CL:0000653). CL:0000653 is a cell type from the Cell Ontology.
Antigen presentation by intrinsic renal cells GO:0019882 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Antigen presentation by intrinsic renal cells, annotated with antigen processing and presentation (GO:0019882). GO:0019882 is a biological process from the Gene Ontology. ↑ INCREASED Cytokine production by intrinsic renal cells GO:0001816 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Cytokine production by intrinsic renal cells, annotated with cytokine production (GO:0001816). GO:0001816 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Intrarenal Immune Cell Conditioning and Activation Antigen presentation and cytokine production by intrinsic renal cells act on the intrarenal immune cells, the second input to their conditioning. Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
Show evidence (1 reference)
PMID:39120952 SUPPORT Other
"The pathways used by intrinsic renal cells to interact with immune cells, such as antigen presentation and cytokine production"
Establishes that intrinsic renal cells engage immune cells through antigen presentation and cytokine production.
Intrarenal Immune Cell Conditioning and Activation
The convergent output of the renal niche and of intrinsic renal cell engagement: the recruitment, survival, differentiation, and activation of the immune cells within the kidney are shaped by the kidney itself. This is the node at which the causal direction reverses relative to the classical cascade, and it feeds back onto both the infiltrate that supplied the cells and the renal cells that conditioned them.
Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
T cell CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology. macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
Activation of intrarenal leukocytes GO:0045321 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Activation of intrarenal leukocytes, annotated with leukocyte activation (GO:0045321). GO:0045321 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu Feedback arm: kidney-conditioned recruitment, survival, and differentiation amplify and sustain the local infiltrate. This edge closes the loop that distinguishes the bidirectional model from the classical unidirectional cascade. Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
Altered Intrinsic Renal Cell Function The second half of the review's reciprocal sentence: the conditioned immune cells in turn modify the function of the kidney's own cells. Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
Show evidence (1 reference)
PMID:39120952 SUPPORT Other
"the kidney microenvironment influences the recruitment, survival, differentiation, and activation of immune cells"
Supports kidney-directed conditioning of intrarenal immune cell recruitment, survival, differentiation, and activation.
Altered Intrinsic Renal Cell Function
The endpoint of the reciprocal arm: intrinsic renal cell function is modified by the immune cells the kidney has conditioned. Modelling this explicitly keeps both halves of the review's reciprocal claim as their own edges rather than leaving the kidney-directed half implicit, and it is the route by which the crosstalk loop contributes to tissue damage.
Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
kidney epithelial cell CL:0002518 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves kidney epithelial cell (CL:0002518). CL:0002518 is a cell type from the Cell Ontology. glomerular mesangial cell CL:1000742 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glomerular mesangial cell (CL:1000742). CL:1000742 is a cell type from the Cell Ontology. podocyte CL:0000653 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves podocyte (CL:0000653). CL:0000653 is a cell type from the Cell Ontology.
Downstream
Glomerular and Tubulointerstitial Injury Immune-cell-driven alteration of intrinsic renal cell function is part of what produces the tissue damage seen in lupus nephritis. Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
Show evidence (1 reference)
PMID:39120952 SUPPORT Other
"which, in turn, modify kidney cell function"
States that the kidney-conditioned immune cells modify kidney cell function.
Glomerular and Tubulointerstitial Injury
Sustained immune-complex, complement, and inflammatory injury produces the graded ISN/RPS histologic spectrum — from mesangial (class I/II) through proliferative (class III/IV) and membranous (class V) disease to end-stage fibrosis (class VI) — with tubulointerstitial disease that also impacts prognosis. Loss of glomerular and tubular function through renal cell death and fibrosis underlies progression to end-stage kidney disease.
podocyte CL:0000653 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves podocyte (CL:0000653). CL:0000653 is a cell type from the Cell Ontology.
Inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:22192660 SUPPORT Human Clinical
"The pathologic classes vary from mild mesangial involvement (Class I) to diffuse proliferative disease (Class IV) to membranous disease (Class V) to end-stage fibrosis (Class VI)."
Describes the graded histopathologic spectrum of glomerular injury in lupus nephritis.
PMID:22192660 SUPPORT Human Clinical
"End-stage renal disease in lupus is secondary to loss of glomerular and tubular function due to renal cell death and resultant fibrosis."
Links glomerular and tubulointerstitial injury to end-stage renal disease.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Lupus Nephritis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Cardiovascular 1
Hypertension HP:0000822 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertension (HP:0000822). HP:0000822 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22192660 SUPPORT Human Clinical
"Co-factors such as hypertension, production of vasoactive substances such as kallikrein, ongoing proteinuria and nephrotoxic drugs play an important role in progression of renal disease in lupus."
Supports hypertension as an important co-factor in lupus nephritis progression.
Genitourinary 3
Nephritis FREQUENT HP:0000123 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nephritis (HP:0000123). HP:0000123 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22192660 SUPPORT Human Clinical
"Nephritis occurs in approximately 50% of lupus patients, but rates vary significantly between genders (men more than women) and ethnicities (more common in people of color)."
Supports nephritis as a frequent (~50%) manifestation among lupus patients.
Proteinuria HP:0000093 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Proteinuria (HP:0000093). HP:0000093 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22192660 SUPPORT Human Clinical
"Development of proteinuria leads to spilling of complement components into the urine."
Documents proteinuria as a feature of lupus nephritis.
Renal Insufficiency / End-Stage Kidney Disease HP:0000083 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Renal insufficiency (HP:0000083), qualified as course progressive. HP:0000083 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:31974366 SUPPORT Human Clinical
"Within 10 years of an initial SLE diagnosis, 5-20% of patients with LN develop end-stage kidney disease"
Quantifies progression of lupus nephritis to end-stage kidney disease.
Other 1
Glomerulonephritis HP:0000099 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Glomerulonephritis (HP:0000099). HP:0000099 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31974366 SUPPORT Human Clinical
"Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE)."
Directly characterizes lupus nephritis as a glomerulonephritis.
💊

Medical Actions

10
Immunosuppressive Induction Therapy
Action: immune suppressant agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immune suppressant agent therapy, annotated with Immunosuppressive Therapy (NCIT:C15261). NCIT:C15261 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunosuppressive Therapy NCIT:C15261
Agent: mycophenolate mofetil CHEBI:8764 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses mycophenolate mofetil (CHEBI:8764). CHEBI:8764 is a therapeutic agent from Chemical Entities of Biological Interest. cyclophosphamide CHEBI:4027 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cyclophosphamide (CHEBI:4027). CHEBI:4027 is a therapeutic agent from Chemical Entities of Biological Interest.
Standard induction therapy for proliferative lupus nephritis combines mycophenolate mofetil or cyclophosphamide with glucocorticoids to suppress the immune-mediated glomerular injury. Mycophenolate mofetil is teratogenic and absolutely contraindicated in the first trimester of pregnancy.
Show evidence (2 references)
PMID:31974366 SUPPORT Human Clinical
"Treatment of LN usually involves immunosuppressive therapy, typically with mycophenolate mofetil or cyclophosphamide and with glucocorticoids"
Establishes mycophenolate mofetil or cyclophosphamide plus glucocorticoids as standard immunosuppressive therapy for LN.
PMID:42420832 SUPPORT Other
"Mycophenolate mofetil is teratogenic and absolutely contraindicated in the first trimester."
Documents mycophenolate mofetil teratogenicity and pregnancy contraindication for lupus nephritis management.
Corticosteroid Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: glucocorticoid CHEBI:24261 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses glucocorticoid (CHEBI:24261). CHEBI:24261 is a therapeutic agent from Chemical Entities of Biological Interest.
Glucocorticoids are a backbone of both induction and maintenance immunosuppression in lupus nephritis.
BAFF Pathway Inhibition (Belimumab)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: belimumab NCIT:C91385 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses belimumab (NCIT:C91385). NCIT:C91385 is a therapeutic agent from the NCI Thesaurus.
Belimumab, a monoclonal antibody against B-cell activating factor (BAFF), added to standard therapy improves renal responses in active lupus nephritis, consistent with the central role of B-cell activation and autoantibody production. Pregnancy registry data for belimumab have not raised major safety signals, allowing selective use in refractory cases.
Show evidence (2 references)
PMID:32937045 SUPPORT Human Clinical
"and a complete renal response (30% vs. 20%; odds ratio, 1.7"
The BLISS-LN trial showed belimumab added to standard therapy improved complete renal response versus placebo.
PMID:42420832 SUPPORT Other
"Belimumab data from the pregnancy registry have not raised major signals; selective use may be considered in refractory cases."
Pregnancy registry data support selective belimumab use in refractory lupus nephritis during pregnancy.
Calcineurin Inhibition (Voclosporin)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: voclosporin NCIT:C152902 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses voclosporin (NCIT:C152902). NCIT:C152902 is a therapeutic agent from the NCI Thesaurus.
Voclosporin, a calcineurin inhibitor, added to mycophenolate mofetil and glucocorticoids significantly increases complete renal response rates in active lupus nephritis. However, voclosporin lacks pregnancy safety data and should be avoided during pregnancy.
Show evidence (2 references)
PMID:33971155 SUPPORT Human Clinical
"complete renal response at week 52 was achieved in significantly more patients"
The AURORA 1 trial demonstrated voclosporin significantly improved complete renal response in lupus nephritis.
PMID:42420832 SUPPORT Other
"Voclosporin and obinutuzumab lack any pregnancy safety data and should be avoided."
Pregnancy safety data for voclosporin are lacking, necessitating avoidance during pregnancy.
Type II Anti-CD20 B Cell Depletion (Obinutuzumab)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: Obinutuzumab NCIT:C70741 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Obinutuzumab (NCIT:C70741). NCIT:C70741 is a therapeutic agent from the NCI Thesaurus.
Obinutuzumab, a type II anti-CD20 monoclonal antibody, added to standard mycophenolate-plus-glucocorticoid therapy, is the most recently approved (2025) lupus nephritis-specific agent, based on the phase 3 REGENCY trial, which met its primary endpoint of complete renal response at week 76.
Mechanism Target:
INHIBITS Autoantibody Production and Immune Complex Formation — Type II anti-CD20 depletion of B cells reduces autoantibody-producing cells and downstream immune-complex-mediated glomerular injury.
Show evidence (2 references)
PMID:39927615 SUPPORT Human Clinical
"complete renal response at week 76 was observed in 46.4% of the patients in the obinutuzumab group and 33.1% of those in the placebo group"
The phase 3 REGENCY trial quantifies the complete-renal-response benefit of adding obinutuzumab to standard therapy.
PMID:39927615 SUPPORT Human Clinical
"Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response."
REGENCY trial conclusion supporting obinutuzumab as an approved lupus nephritis therapy.
Antimalarial Background Therapy (Hydroxychloroquine)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: hydroxychloroquine CHEBI:5801 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses hydroxychloroquine (CHEBI:5801). CHEBI:5801 is a therapeutic agent from Chemical Entities of Biological Interest.
Hydroxychloroquine is recommended as background therapy for all patients with SLE, including those with lupus nephritis. Hydroxychloroquine remains a cornerstone of pregnancy-compatible lupus nephritis management.
Show evidence (1 reference)
PMID:42420832 SUPPORT Other
"Hydroxychloroquine and azathioprine remain the cornerstones of pregnancy-compatible LN management."
Documents hydroxychloroquine as a safe, pregnancy-compatible cornerstone therapy for lupus nephritis.
Azathioprine Maintenance Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: azathioprine CHEBI:2948 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses azathioprine (CHEBI:2948). CHEBI:2948 is a therapeutic agent from Chemical Entities of Biological Interest.
Azathioprine is a pregnancy-compatible immunosuppressive agent that remains a cornerstone of pregnancy-safe lupus nephritis management and can be used as a maintenance therapy option.
Show evidence (1 reference)
PMID:42420832 SUPPORT Other
"Hydroxychloroquine and azathioprine remain the cornerstones of pregnancy-compatible LN management."
Identifies azathioprine as a cornerstone, pregnancy-compatible immunosuppressive for lupus nephritis.
Calcineurin Inhibition (Tacrolimus)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: tacrolimus CHEBI:61049 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses tacrolimus, annotated with tacrolimus (anhydrous) (CHEBI:61049). CHEBI:61049 is a therapeutic agent from Chemical Entities of Biological Interest.
Tacrolimus is an acceptable calcineurin inhibitor alternative for pregnancy-compatible lupus nephritis management, requiring appropriate therapeutic drug monitoring.
Show evidence (1 reference)
PMID:42420832 SUPPORT Other
"Tacrolimus is an acceptable calcineurin inhibitor with appropriate therapeutic drug monitoring."
Establishes tacrolimus as a pregnancy-compatible calcineurin inhibitor option for lupus nephritis with drug monitoring.
B Cell Depletion Therapy (Rituximab) — Pregnancy-Cautious Use
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: rituximab NCIT:C1702 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses rituximab (NCIT:C1702). NCIT:C1702 is a therapeutic agent from the NCI Thesaurus.
Rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, may be used cautiously for life-threatening lupus nephritis during pregnancy, but should be avoided in the third trimester due to risk of neonatal B-cell depletion.
Show evidence (1 reference)
PMID:42420832 SUPPORT Other
"Rituximab may be used cautiously for life-threatening disease, avoiding the third trimester due to neonatal B-cell depletion."
Documents rituximab as a cautious, life-threatening-disease-only option in pregnancy, with third-trimester avoidance.
Antiplatelet Therapy for Preeclampsia Prevention
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: acetylsalicylic acid CHEBI:15365 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses acetylsalicylic acid (CHEBI:15365). CHEBI:15365 is a therapeutic agent from Chemical Entities of Biological Interest.
Low-dose aspirin is recommended universally in lupus nephritis pregnancy management to reduce the risk of preeclampsia, a major pregnancy complication in this population.
Show evidence (1 reference)
PMID:42420832 SUPPORT Other
"Low-dose aspirin is recommended universally to reduce preeclampsia risk."
Establishes low-dose aspirin as universal preeclampsia prevention in lupus nephritis pregnancies.
📊

Prevalence

1
Patients with systemic lupus erythematosus
Period Prevalence 50000.0 per 100,000 Common
Nephritis develops in roughly half of SLE patients, with higher rates and worse outcomes in men and in people of color; most LN develops within 5 years of SLE diagnosis and LN is frequently the presenting manifestation.
Show evidence (2 references)
PMID:22192660 SUPPORT Human Clinical
"Nephritis occurs in approximately 50% of lupus patients, but rates vary significantly between genders (men more than women) and ethnicities (more common in people of color)."
Quantifies the fraction of SLE patients who develop nephritis and its demographic variation.
PMID:31974366 SUPPORT Human Clinical
"Most patients with SLE who develop LN do so within 5 years of an SLE diagnosis and, in many cases, LN is the presenting manifestation resulting in the diagnosis of SLE"
Supports the early-onset timing of LN within the SLE disease course.
📊

Related Datasets

6
Based on single-cell sequencing analysis of CD4+ T cells and B cells in patients with lupus nephritis, the heterogeneity of these cells was investigated. geo:GSE306378
Utilizing single-cell technology to analyze the heterogeneity of CD4+ T cells and B cells in patients with lupus nephritis.We have delineated the immune cell profile of PBMC in LN patients, and focused on describing the heterogeneity characteristics of CD4+ T cells and B cells. Some specific cell subtypes and ligand-receptor pairs were identified, which indicate potential therapeutic targets for lupus erythematosus.
human SINGLE CELL RNA SEQ n=6
PMID:41540405
Identified by GEO DataSets index search for Lupus Nephritis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Lupus nephritis serum induces changes in gene expression in human glomerular endothelial cells, which is modulated by L-sepiapterin: Implications for redox-mediated endothelial dysfunction geo:GSE296560
Lupus nephritis (LN) is characterized by renal endothelial dysfunction, which contributes to progressive kidney injury. Endothelial nitric oxide synthase (eNOS) plays a modulating role in LN, as genetic ablation of the eNOS enzyme worsens disease. Serum from patients with active LN induces uncoupling of eNOS homodimers, leading to superoxide (SO) rather than nitric oxide (NO) production by eNOS. This uncoupling is reversed with L-sepiapterin (L-Sep). This study was designed to further examine changes in gene expression in glomerular endothelial cells induced by LN serum and whether treatment with L-Sep can ameliorate these changes.
human BULK RNA SEQ n=19
PMID:40480647
Identified by GEO DataSets index search for Lupus Nephritis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Single-cell transcriptomes and T cell receptor sequences of CD4 or CD8 single positive T lymphocytes from peripheral blood or urine of lupus nephritis patients at flare. geo:GSE322527
Proliferative lupus nephritis (LN) is triggered by deposition of autoantibodies in glomeruli and paralleled by a T cell-rich kidney infiltrate. Although these T cells have been attributed with propagation of tissue injury, it is unclear how they are activated and whether T cell autoreactivity drives the local inflammation. Kidney-infiltrating T cells are also observed in urine, where they have high resemblance with interstitial T cells. Therefore, urinary T cells are a proxy to investigate tissue pathogenesis. Here, we analyzed urinary T cells to elucidate if a kidney-specific T cell autoimmune reaction contributes to tubulointerstitial inflammation in LN.
human SINGLE CELL RNA SEQ n=26
Identified by GEO DataSets index search for Lupus Nephritis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Identification of Long Non-coding RNA Biomarker of Human Lupus Nephritis Disease Activity ega:EGAS00001007117
Total RNA sequencing was performed on whole blood samples from 74 Lupus nephritis (LN) patients and 20 healthy controls. Differential expression analysis and weighted gene co-expression network analysis were performed to characterise expression changes of long non-coding RNAs (lncRNAs) in LN and identify lncRNAs with a key role in disease activity that could be used as potential blood-based biomarkers.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Lupus Nephritis"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
ScRNA-seq of human kidney immune cells of patients with ANCA-associated glomerulonephritis, Lupus Nephritis against a "healthy" nephrectomy control ega:EGAS50000000159
ANCA-associated glomerulonephritis (AGN) associates with a high risk of end-stage kidney disease. The role of kidney immune cells in local inflammation remains unclear. Here, we investigate kidney immune cell diversity and function. Kidney tissue from AGN patients (n=5) and a lupus nephritis (LN) patient (n=1) were aquired during a biopsy procedure for a clinical indication. Needle-core biopsies were obtained for histopathological examination, and an additional pass was performed to retrieve kidney tissue for scRNA-seq. Healthy kidney tissue (n=1) was obtained from a kidney that was surgically removed do tue due to a (non-invasive) papillary urothelial carcinoma.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Lupus Nephritis"); description-level mentions were not accepted. EGA study_type: RNASeq. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Genetic Contributions of Lupus Nephritis in A Multi-Ethnic Cohort dbgap:phs001609
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) and it occurs at a much higher rate in patients that are not of European descent. The purpose of this study is to identify genetic variants contributing to the risk of LN in a multi-ethnic cohort of SLE patients. We used a comprehensive genome-wide screen and 1244 SLE patients from 5 different ethnic groups. In genome-wide gene-based and candidate SNP analyses, we found distinct genes and pathways, and established risk SNPs associated with lupus nephritis for each ethnic group.
Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Lupus Nephritis"). Retrieved 2026-08-02.
{ }

Source YAML

click to show 
name: Lupus Nephritis
creation_date: '2026-07-10T18:30:00Z'
description: >-
  Lupus nephritis is an immune-complex glomerulonephritis that is one of the most
  severe organ manifestations of systemic lupus erythematosus (SLE). Anti-dsDNA and
  anti-chromatin (anti-nucleosome) autoantibodies form immune complexes that deposit
  in — or bind in situ to nucleosomes/DNA within — the glomerulus, driving complement
  activation, Fc-receptor and Toll-like-receptor engagement, and inflammatory tissue
  injury. The clinicopathologic spectrum is graded by the ISN/RPS classification from
  mild mesangial involvement (class I/II) through focal and diffuse proliferative
  disease (class III/IV) and membranous disease (class V) to advanced sclerosis
  (class VI), and manifests clinically with proteinuria, an active urinary sediment,
  hypertension, and progression to chronic kidney disease or end-stage kidney disease.
category: Complex
disease_term:
  preferred_term: lupus nephritis
  term:
    id: MONDO:0005556
    label: lupus nephritis
classifications:
  harrisons_chapter:
  - classification_value: KIDNEY_URINARY_TRACT
  - classification_value: IMMUNE_RHEUMATOLOGIC
inheritance:
- name: Polygenic / multifactorial susceptibility
  inheritance_term:
    preferred_term: Polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  description: >-
    Lupus nephritis has no simple Mendelian inheritance. Renal susceptibility within
    SLE is multifactorial, with contributions from complement-pathway genes, Fc-gamma
    receptor (FcgR) gene variants and copy-number changes, and HLA and interferon-axis
    loci, modified by sex and ancestry. Rare early-complement-component (e.g. C1q)
    deficiency is a strong monogenic risk factor for lupus.
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Similarly, reports of associations of FcγR genetic changes with nephritis appear linked to specific ethnicities"
    explanation: Supports a polygenic, ancestry-modified genetic contribution (FcgR variants) to lupus nephritis susceptibility.
prevalence:
- population: Patients with systemic lupus erythematosus
  measure_type: PERIOD_PREVALENCE
  prevalence_class: COMMON
  rate_per_100000: 50000.0
  notes: >-
    Nephritis develops in roughly half of SLE patients, with higher rates and worse
    outcomes in men and in people of color; most LN develops within 5 years of SLE
    diagnosis and LN is frequently the presenting manifestation.
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nephritis occurs in approximately 50% of lupus patients, but rates vary significantly between genders (men more than women) and ethnicities (more common in people of color)."
    explanation: Quantifies the fraction of SLE patients who develop nephritis and its demographic variation.
  - reference: PMID:31974366
    reference_title: "Lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients with SLE who develop LN do so within 5 years of an SLE diagnosis and, in many cases, LN is the presenting manifestation resulting in the diagnosis of SLE"
    explanation: Supports the early-onset timing of LN within the SLE disease course.
mechanistic_hypotheses:
- hypothesis_group_id: unidirectional_immune_injury_model
  hypothesis_label: Unidirectional Immune-Complex Injury Model
  status: CANONICAL
  description: >-
    The classical account treats the kidney as a passive target of systemic
    autoimmunity: autoreactive B cells and plasma cells generate anti-dsDNA and
    anti-chromatin antibodies, the resulting immune complexes deposit in — or bind
    in situ within — the glomerulus, and complement, Fc-receptor, and
    Toll-like-receptor engagement drive inflammatory glomerular and
    tubulointerstitial injury. Causal flow runs in one direction, from systemic
    autoimmunity to renal tissue damage, and this model underwrites systemic
    immunosuppression as the therapeutic strategy.
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic anti-dsDNA antibodies deposit as immune complexes"
    explanation: Supports the autoantibody-to-deposition step that opens the unidirectional chain.
  - reference: PMID:39120952
    reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It is now increasingly appreciated that LN is not due to unidirectional immune cell activation with subsequent kidney damage."
    explanation: >-
      This review does not dispute that immune-complex-driven activation causes renal
      injury, but holds the strictly unidirectional framing to be an incomplete account
      of lupus nephritis — hence PARTIAL rather than SUPPORT for the model as a whole.
- hypothesis_group_id: bidirectional_kidney_immune_crosstalk
  hypothesis_label: Bidirectional Kidney Microenvironment-Immune Cell Crosstalk Model
  status: EMERGING
  description: >-
    An extension in which the kidney is an active participant rather than a passive
    target. The renal biochemical niche (low oxygen tension and hypertonicity) together
    with intrinsic renal cell types — which can present antigen and produce cytokines —
    shapes the recruitment, survival, differentiation, and activation of the intrarenal
    immune infiltrate; those conditioned immune cells in turn modify kidney cell
    function, closing a self-amplifying loop. The model does not replace the
    immune-complex cascade; it adds a reciprocal arm downstream of it, and it predicts
    that kidney-targeted rather than systemic intervention could interrupt the loop.
  evidence:
  - reference: PMID:39120952
    reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the kidney microenvironment influences the recruitment, survival, differentiation, and activation of immune cells, which, in turn, modify kidney cell function"
    explanation: States the reciprocal kidney-to-immune-cell and immune-cell-to-kidney arms that define this model.
  notes: >-
    Status is EMERGING rather than CANONICAL because the supporting citation is a
    narrative review synthesizing largely mechanistic and model-system work; the
    reciprocal arm has not been shown to drive human renal outcomes independently of
    the immune-complex cascade.
pathophysiology:
- name: Autoantibody Production and Immune Complex Formation
  description: >-
    Failure of B-cell tolerance in SLE generates anti-dsDNA and anti-chromatin
    (anti-nucleosome) autoantibodies from autoreactive B cells and plasma cells.
    These antibodies to DNA/nucleosomes are the autoantibody species most closely
    linked to the development of nephritis and form circulating and in-situ immune
    complexes.
  biological_processes:
  - preferred_term: Immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
    modifier: INCREASED
  - preferred_term: Humoral immune response mediated by circulating immunoglobulin
    term:
      id: GO:0002455
      label: humoral immune response mediated by circulating immunoglobulin
    modifier: ABNORMAL
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  downstream:
  - target: Glomerular Immune Complex Deposition
    description: Pathogenic anti-dsDNA/anti-chromatin antibodies deposit as immune complexes in the glomerulus.
    causal_link_type: DIRECT
    hypothesis_groups:
    - unidirectional_immune_injury_model
    evidence:
    - reference: PMID:22192660
      reference_title: "Mechanisms of tissue injury in lupus nephritis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pathogenic anti-dsDNA antibodies deposit as immune complexes"
      explanation: Links the autoantibody response directly to glomerular immune-complex deposition.
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Antibodies to dsDNA/nucleosomes are most closely linked with development of nephritis"
    explanation: Identifies anti-dsDNA/nucleosome antibodies as the autoantibody species most associated with lupus nephritis.
  - reference: PMID:42413709
    reference_title: "Reflections on chromatin structures, corresponding autoantibodies - And conflicting dogmas impacting pathogenesis of lupus nephritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "anti-DNA antibody structures and anti-chromatin antibodies; their origins, and their impact on operational molecular and cellular processes accounting for lupus nephritis"
    explanation: Situates chromatin-directed autoantibodies at the center of the molecular and cellular processes producing lupus nephritis.
- name: Glomerular Immune Complex Deposition
  description: >-
    Immune complexes accumulate in the glomerulus both by deposition of circulating
    complexes and by in-situ binding of anti-dsDNA/chromatin antibodies to nucleosomes
    and DNA present in the glomerular matrix, engaging mesangial cells, glomerular
    endothelium, and podocytes across the mesangial, subendothelial, and subepithelial
    compartments that define the ISN/RPS histologic classes.
  cell_types:
  - preferred_term: glomerular mesangial cell
    term:
      id: CL:1000742
      label: glomerular mesangial cell
  - preferred_term: glomerular capillary endothelial cell
    term:
      id: CL:1001005
      label: glomerular capillary endothelial cell
  - preferred_term: podocyte
    term:
      id: CL:0000653
      label: podocyte
  downstream:
  - target: Complement Activation and Glomerular Inflammation
    description: Deposited immune complexes co-stimulate Fc receptors and endosomal TLRs and activate complement.
    causal_link_type: DIRECT
    hypothesis_groups:
    - unidirectional_immune_injury_model
    evidence:
    - reference: PMID:22192660
      reference_title: "Mechanisms of tissue injury in lupus nephritis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These complexes can then lead to further activation of immune pathways by co-stimulation of FcγRs and endosomal Toll-like receptors (TLRs) and/or by activating the complement cascade"
      explanation: Connects glomerular immune-complex deposition to downstream Fc-receptor, TLR, and complement activation.
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "anti-dsDNA/chromatin antibodies binding to nucleosomes/DNA present in the glomerular matrix, as the most compelling"
    explanation: Supports the in-situ binding mechanism of glomerular immune-complex formation.
- name: Complement Activation and Glomerular Inflammation
  description: >-
    Glomerular immune complexes activate the complement cascade — deposition of
    complement proteins in glomeruli is a hallmark of lupus nephritis — and recruit
    macrophages and other leukocytes, producing an inflammatory glomerular
    microenvironment. Concurrent anti-C1q antibodies accelerate renal disease.
  biological_processes:
  - preferred_term: Complement activation, classical pathway
    term:
      id: GO:0006958
      label: complement activation, classical pathway
    modifier: INCREASED
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Glomerular and Tubulointerstitial Injury
    description: Complement activation and inflammatory infiltration are deleterious, driving glomerular and tubular tissue injury.
    causal_link_type: DIRECT
    hypothesis_groups:
    - unidirectional_immune_injury_model
    evidence:
    - reference: PMID:22192660
      reference_title: "Mechanisms of tissue injury in lupus nephritis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "There is strong evidence that complement activation is deleterious in lupus nephritis"
      explanation: Links complement activation to tissue injury in lupus nephritis.
  - target: Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu
    description: >-
      Complement- and Fc-receptor-driven glomerular inflammation recruits leukocytes
      into the kidney, establishing the intrarenal immune infiltrate and cytokine
      milieu that characterizes the lupus kidney.
    causal_link_type: DIRECT
    hypothesis_groups:
    - bidirectional_kidney_immune_crosstalk
    evidence:
    - reference: PMID:39120952
      reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The kidney in LN is characterized by a significant immune infiltrate and proinflammatory cytokine milieu"
      explanation: Establishes the intrarenal immune infiltrate and cytokine milieu as the state reached downstream of glomerular inflammation.
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deposition of complement proteins in glomeruli is a key feature of lupus nephritis."
    explanation: Establishes glomerular complement deposition as a defining feature of lupus nephritis.
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When anti-C1q antibodies are present along with anti-dsDNA antibodies, development of renal disease is accelerated"
    explanation: Supports anti-C1q antibodies as an accelerant of complement-driven renal disease.
- name: Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu
  biological_scale: TISSUE
  description: >-
    Downstream of complement and Fc-receptor activation, the lupus kidney accumulates
    a substantial infiltrate of T cells, macrophages, and other leukocytes together
    with a proinflammatory cytokine milieu. This intrarenal compartment is not merely
    a bystander readout of systemic autoimmunity: the infiltrating cells and the
    cytokines they produce act directly on intrinsic renal cells, and are in part
    responsible for the tissue damage seen in lupus nephritis.
  biological_processes:
  - preferred_term: Leukocyte migration into the kidney
    term:
      id: GO:0050900
      label: leukocyte migration
    modifier: INCREASED
  - preferred_term: Proinflammatory cytokine production
    term:
      id: GO:0001816
      label: cytokine production
    modifier: INCREASED
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Intrinsic Renal Cell Antigen Presentation and Cytokine Production
    description: >-
      Infiltrating immune cells and their cytokines act on intrinsic renal cells,
      engaging the renal-cell arm of the reciprocal loop. Note this edge deliberately
      targets the induced renal-cell activity, not the renal biochemical niche, which
      is constitutive rather than immune-induced. Evidence caveat: the cited abstract
      states a general effect on intrinsic renal cells ("affects intrinsic renal
      cells") and describes antigen presentation and cytokine production in the
      renal-to-immune direction; that the infiltrate specifically induces those two
      pathways is a reasonable inference from the review's framing rather than a
      sentence it states, so the specificity of this edge is weaker than its direction.
    causal_link_type: DIRECT
    hypothesis_groups:
    - bidirectional_kidney_immune_crosstalk
    evidence:
    - reference: PMID:39120952
      reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The kidney in LN is characterized by a significant immune infiltrate and proinflammatory cytokine milieu that affects intrinsic renal cells"
      explanation: Establishes that the intrarenal infiltrate and cytokine milieu act upon intrinsic renal cells.
  - target: Glomerular and Tubulointerstitial Injury
    description: >-
      The intrarenal infiltrate and cytokine milieu are in part directly responsible
      for the tissue damage observed in lupus nephritis.
    causal_link_type: DIRECT
    hypothesis_groups:
    - unidirectional_immune_injury_model
    - bidirectional_kidney_immune_crosstalk
    evidence:
    - reference: PMID:39120952
      reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "proinflammatory cytokine milieu that affects intrinsic renal cells and is, in part, responsible for the tissue damage observed in LN"
      explanation: Attributes part of the renal tissue damage directly to the intrarenal cytokine milieu.
  evidence:
  - reference: PMID:39120952
    reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The kidney in LN is characterized by a significant immune infiltrate and proinflammatory cytokine milieu"
    explanation: Supports the intrarenal immune infiltrate and cytokine milieu as a defining feature of the lupus kidney.
- name: Renal Biochemical Niche (Low Oxygen Tension and Hypertonicity)
  biological_scale: TISSUE
  description: >-
    The kidney's distinctive biochemical environment — the low oxygen tension of the
    corticomedullary gradient and the hypertonicity of the medullary interstitium —
    is a constitutive feature of normal renal physiology, not a state induced by
    lupus. It is modelled here as an initiating, contextual node because it is the
    pre-existing environment that infiltrating immune cells arrive into, and it shapes
    how those cells behave once they are there. It therefore carries no incoming edge
    from the immune infiltrate.
  biological_processes:
  - preferred_term: Renal cellular response to low oxygen tension
    term:
      id: GO:0071456
      label: cellular response to hypoxia
  - preferred_term: Response to medullary hypertonicity
    term:
      id: GO:0006972
      label: hyperosmotic response
  cell_types:
  - preferred_term: kidney epithelial cell
    term:
      id: CL:0002518
      label: kidney epithelial cell
  - preferred_term: kidney tubule cell
    term:
      id: CL:1000507
      label: kidney tubule cell
  downstream:
  - target: Intrarenal Immune Cell Conditioning and Activation
    description: >-
      The renal biochemical niche acts on the immune cells that enter it, shaping
      their behaviour within the kidney.
    causal_link_type: DIRECT
    hypothesis_groups:
    - bidirectional_kidney_immune_crosstalk
    evidence:
    - reference: PMID:39120952
      reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "low oxygen tension and hypertonicity) and unique kidney cell types affect the intrarenal immune cells in LN"
      explanation: States that the renal biochemical environment affects the intrarenal immune cells.
  evidence:
  - reference: PMID:39120952
    reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "low oxygen tension and hypertonicity) and unique kidney cell types affect the intrarenal immune cells in LN"
    explanation: Identifies low oxygen tension and hypertonicity as the biochemical environment of the kidney in this model.
  notes: >-
    No modifier is asserted on either process: the review treats these as the kidney's
    normal biochemical conditions, so neither is curated as increased or decreased
    relative to a healthy kidney. Term choice: GO:0071456 and GO:0006972 name the
    cells' responses to hypoxia and hypertonicity, whereas this node models the niche
    itself as an environment. No better handle exists — an environment is a PATO/ENVO
    concept and this is intrinsic renal physiology rather than an exposure, so ECTO
    does not apply either — and per the "no term beats a bad one" rule these are kept
    with preferred_term values that name the niche.
- name: Intrinsic Renal Cell Antigen Presentation and Cytokine Production
  biological_scale: CELLULAR
  description: >-
    Intrinsic renal cells are not passive bystanders to the infiltrate. They interact
    with intrarenal immune cells through defined pathways — notably antigen
    presentation and cytokine production — and so participate directly in local immune
    regulation. Unlike the biochemical niche, this activity is induced by, and
    downstream of, the intrarenal immune infiltrate.
  biological_processes:
  - preferred_term: Antigen presentation by intrinsic renal cells
    term:
      id: GO:0019882
      label: antigen processing and presentation
    modifier: INCREASED
  - preferred_term: Cytokine production by intrinsic renal cells
    term:
      id: GO:0001816
      label: cytokine production
    modifier: INCREASED
  cell_types:
  - preferred_term: kidney epithelial cell
    term:
      id: CL:0002518
      label: kidney epithelial cell
  - preferred_term: kidney tubule cell
    term:
      id: CL:1000507
      label: kidney tubule cell
  - preferred_term: glomerular mesangial cell
    term:
      id: CL:1000742
      label: glomerular mesangial cell
  - preferred_term: podocyte
    term:
      id: CL:0000653
      label: podocyte
  downstream:
  - target: Intrarenal Immune Cell Conditioning and Activation
    description: >-
      Antigen presentation and cytokine production by intrinsic renal cells act on the
      intrarenal immune cells, the second input to their conditioning.
    causal_link_type: DIRECT
    hypothesis_groups:
    - bidirectional_kidney_immune_crosstalk
    evidence:
    - reference: PMID:39120952
      reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The pathways used by intrinsic renal cells to interact with immune cells, such as antigen presentation and cytokine production"
      explanation: Names antigen presentation and cytokine production as the pathways by which intrinsic renal cells act on immune cells.
  evidence:
  - reference: PMID:39120952
    reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The pathways used by intrinsic renal cells to interact with immune cells, such as antigen presentation and cytokine production"
    explanation: Establishes that intrinsic renal cells engage immune cells through antigen presentation and cytokine production.
- name: Intrarenal Immune Cell Conditioning and Activation
  biological_scale: CELLULAR
  description: >-
    The convergent output of the renal niche and of intrinsic renal cell engagement:
    the recruitment, survival, differentiation, and activation of the immune cells
    within the kidney are shaped by the kidney itself. This is the node at which the
    causal direction reverses relative to the classical cascade, and it feeds back
    onto both the infiltrate that supplied the cells and the renal cells that
    conditioned them.
  biological_processes:
  - preferred_term: Activation of intrarenal leukocytes
    term:
      id: GO:0045321
      label: leukocyte activation
    modifier: INCREASED
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu
    description: >-
      Feedback arm: kidney-conditioned recruitment, survival, and differentiation
      amplify and sustain the local infiltrate. This edge closes the loop that
      distinguishes the bidirectional model from the classical unidirectional cascade.
    causal_link_type: DIRECT
    hypothesis_groups:
    - bidirectional_kidney_immune_crosstalk
    evidence:
    - reference: PMID:39120952
      reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "the kidney microenvironment influences the recruitment, survival, differentiation, and activation of immune cells"
      explanation: States the kidney-to-immune-cell arm of the loop that this edge represents.
  - target: Altered Intrinsic Renal Cell Function
    description: >-
      The second half of the review's reciprocal sentence: the conditioned immune
      cells in turn modify the function of the kidney's own cells.
    causal_link_type: DIRECT
    hypothesis_groups:
    - bidirectional_kidney_immune_crosstalk
    evidence:
    - reference: PMID:39120952
      reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "the kidney microenvironment influences the recruitment, survival, differentiation, and activation of immune cells, which, in turn, modify kidney cell function"
      explanation: The trailing clause states that the conditioned immune cells modify kidney cell function.
  evidence:
  - reference: PMID:39120952
    reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the kidney microenvironment influences the recruitment, survival, differentiation, and activation of immune cells"
    explanation: Supports kidney-directed conditioning of intrarenal immune cell recruitment, survival, differentiation, and activation.
- name: Altered Intrinsic Renal Cell Function
  biological_scale: CELLULAR
  description: >-
    The endpoint of the reciprocal arm: intrinsic renal cell function is modified by
    the immune cells the kidney has conditioned. Modelling this explicitly keeps both
    halves of the review's reciprocal claim as their own edges rather than leaving the
    kidney-directed half implicit, and it is the route by which the crosstalk loop
    contributes to tissue damage.
  cell_types:
  - preferred_term: kidney epithelial cell
    term:
      id: CL:0002518
      label: kidney epithelial cell
  - preferred_term: glomerular mesangial cell
    term:
      id: CL:1000742
      label: glomerular mesangial cell
  - preferred_term: podocyte
    term:
      id: CL:0000653
      label: podocyte
  downstream:
  - target: Glomerular and Tubulointerstitial Injury
    description: >-
      Immune-cell-driven alteration of intrinsic renal cell function is part of what
      produces the tissue damage seen in lupus nephritis.
    causal_link_type: DIRECT
    hypothesis_groups:
    - bidirectional_kidney_immune_crosstalk
    evidence:
    - reference: PMID:39120952
      reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "proinflammatory cytokine milieu that affects intrinsic renal cells and is, in part, responsible for the tissue damage observed in LN"
      explanation: Links the effect on intrinsic renal cells to the tissue damage observed in lupus nephritis.
  evidence:
  - reference: PMID:39120952
    reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "which, in turn, modify kidney cell function"
    explanation: States that the kidney-conditioned immune cells modify kidney cell function.
  notes: >-
    Curated from a narrative review, so this arm records a mechanism the review
    synthesizes rather than a single-study finding; the review does not quantify how
    much of the tissue damage in lupus nephritis proceeds through this route.
- name: Glomerular and Tubulointerstitial Injury
  description: >-
    Sustained immune-complex, complement, and inflammatory injury produces the graded
    ISN/RPS histologic spectrum — from mesangial (class I/II) through proliferative
    (class III/IV) and membranous (class V) disease to end-stage fibrosis (class VI) —
    with tubulointerstitial disease that also impacts prognosis. Loss of glomerular and
    tubular function through renal cell death and fibrosis underlies progression to
    end-stage kidney disease.
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  cell_types:
  - preferred_term: podocyte
    term:
      id: CL:0000653
      label: podocyte
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pathologic classes vary from mild mesangial involvement (Class I) to diffuse proliferative disease (Class IV) to membranous disease (Class V) to end-stage fibrosis (Class VI)."
    explanation: Describes the graded histopathologic spectrum of glomerular injury in lupus nephritis.
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "End-stage renal disease in lupus is secondary to loss of glomerular and tubular function due to renal cell death and resultant fibrosis."
    explanation: Links glomerular and tubulointerstitial injury to end-stage renal disease.
phenotypes:
- name: Glomerulonephritis
  category: Renal
  description: Lupus nephritis is fundamentally a form of glomerulonephritis, one of the most severe organ manifestations of SLE.
  phenotype_term:
    preferred_term: Glomerulonephritis
    term:
      id: HP:0000099
      label: Glomerulonephritis
  evidence:
  - reference: PMID:31974366
    reference_title: "Lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE)."
    explanation: Directly characterizes lupus nephritis as a glomerulonephritis.
- name: Nephritis
  category: Renal
  description: Renal inflammation (nephritis) develops in approximately half of SLE patients.
  phenotype_term:
    preferred_term: Nephritis
    term:
      id: HP:0000123
      label: Nephritis
  frequency: FREQUENT
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nephritis occurs in approximately 50% of lupus patients, but rates vary significantly between genders (men more than women) and ethnicities (more common in people of color)."
    explanation: Supports nephritis as a frequent (~50%) manifestation among lupus patients.
- name: Proteinuria
  category: Renal
  description: Proteinuria is a cardinal manifestation and disease-activity readout in lupus nephritis.
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: Proteinuria
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Development of proteinuria leads to spilling of complement components into the urine."
    explanation: Documents proteinuria as a feature of lupus nephritis.
- name: Hypertension
  category: Cardiovascular
  description: Hypertension is a common co-factor that contributes to progression of renal disease in lupus nephritis.
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Co-factors such as hypertension, production of vasoactive substances such as kallikrein, ongoing proteinuria and nephrotoxic drugs play an important role in progression of renal disease in lupus."
    explanation: Supports hypertension as an important co-factor in lupus nephritis progression.
- name: Renal Insufficiency / End-Stage Kidney Disease
  category: Renal
  description: >-
    Progressive loss of renal function culminating in end-stage kidney disease occurs
    in a substantial minority of patients; 5-20% of patients with LN reach end-stage
    kidney disease within 10 years of SLE diagnosis.
  phenotype_term:
    preferred_term: Renal insufficiency
    term:
      id: HP:0000083
      label: Renal insufficiency
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:31974366
    reference_title: "Lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Within 10 years of an initial SLE diagnosis, 5-20% of patients with LN develop end-stage kidney disease"
    explanation: Quantifies progression of lupus nephritis to end-stage kidney disease.
treatments:
- name: Immunosuppressive Induction Therapy
  description: >-
    Standard induction therapy for proliferative lupus nephritis combines
    mycophenolate mofetil or cyclophosphamide with glucocorticoids to suppress the
    immune-mediated glomerular injury. Mycophenolate mofetil is teratogenic and
    absolutely contraindicated in the first trimester of pregnancy.
  treatment_term:
    preferred_term: immune suppressant agent therapy
    term:
      id: NCIT:C15261
      label: Immunosuppressive Therapy
    therapeutic_agent:
    - preferred_term: mycophenolate mofetil
      term:
        id: CHEBI:8764
        label: mycophenolate mofetil
    - preferred_term: cyclophosphamide
      term:
        id: CHEBI:4027
        label: cyclophosphamide
  evidence:
  - reference: PMID:31974366
    reference_title: "Lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of LN usually involves immunosuppressive therapy, typically with mycophenolate mofetil or cyclophosphamide and with glucocorticoids"
    explanation: Establishes mycophenolate mofetil or cyclophosphamide plus glucocorticoids as standard immunosuppressive therapy for LN.
  - reference: PMID:42420832
    reference_title: "Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mycophenolate mofetil is teratogenic and absolutely contraindicated in the first trimester."
    explanation: Documents mycophenolate mofetil teratogenicity and pregnancy contraindication for lupus nephritis management.
- name: Corticosteroid Therapy
  description: Glucocorticoids are a backbone of both induction and maintenance immunosuppression in lupus nephritis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: glucocorticoid
      term:
        id: CHEBI:24261
        label: glucocorticoid
  notes: Used with mycophenolate mofetil or cyclophosphamide as part of standard LN regimens.
- name: BAFF Pathway Inhibition (Belimumab)
  description: >-
    Belimumab, a monoclonal antibody against B-cell activating factor (BAFF), added to
    standard therapy improves renal responses in active lupus nephritis, consistent with
    the central role of B-cell activation and autoantibody production. Pregnancy registry
    data for belimumab have not raised major safety signals, allowing selective use in
    refractory cases.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: belimumab
      term:
        id: NCIT:C91385
        label: Belimumab
  evidence:
  - reference: PMID:32937045
    reference_title: "Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and a complete renal response (30% vs. 20%; odds ratio, 1.7"
    explanation: The BLISS-LN trial showed belimumab added to standard therapy improved complete renal response versus placebo.
  - reference: PMID:42420832
    reference_title: "Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Belimumab data from the pregnancy registry have not raised major signals; selective use may be considered in refractory cases."
    explanation: Pregnancy registry data support selective belimumab use in refractory lupus nephritis during pregnancy.
- name: Calcineurin Inhibition (Voclosporin)
  description: >-
    Voclosporin, a calcineurin inhibitor, added to mycophenolate mofetil and
    glucocorticoids significantly increases complete renal response rates in active
    lupus nephritis. However, voclosporin lacks pregnancy safety data and should be
    avoided during pregnancy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: voclosporin
      term:
        id: NCIT:C152902
        label: Voclosporin
  evidence:
  - reference: PMID:33971155
    reference_title: "Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complete renal response at week 52 was achieved in significantly more patients"
    explanation: The AURORA 1 trial demonstrated voclosporin significantly improved complete renal response in lupus nephritis.
  - reference: PMID:42420832
    reference_title: "Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Voclosporin and obinutuzumab lack any pregnancy safety data and should be avoided."
    explanation: Pregnancy safety data for voclosporin are lacking, necessitating avoidance during pregnancy.
- name: Type II Anti-CD20 B Cell Depletion (Obinutuzumab)
  description: >-
    Obinutuzumab, a type II anti-CD20 monoclonal antibody, added to standard
    mycophenolate-plus-glucocorticoid therapy, is the most recently approved
    (2025) lupus nephritis-specific agent, based on the phase 3 REGENCY trial,
    which met its primary endpoint of complete renal response at week 76.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Obinutuzumab
      term:
        id: NCIT:C70741
        label: Obinutuzumab
  target_mechanisms:
  - target: Autoantibody Production and Immune Complex Formation
    treatment_effect: INHIBITS
    description: >-
      Type II anti-CD20 depletion of B cells reduces autoantibody-producing
      cells and downstream immune-complex-mediated glomerular injury.
  evidence:
  - reference: PMID:39927615
    reference_title: "Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complete renal response at week 76 was observed in 46.4% of the patients in the obinutuzumab group and 33.1% of those in the placebo group"
    explanation: The phase 3 REGENCY trial quantifies the complete-renal-response benefit of adding obinutuzumab to standard therapy.
  - reference: PMID:39927615
    reference_title: "Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response."
    explanation: REGENCY trial conclusion supporting obinutuzumab as an approved lupus nephritis therapy.
- name: Antimalarial Background Therapy (Hydroxychloroquine)
  description: >-
    Hydroxychloroquine is recommended as background therapy for all patients with SLE,
    including those with lupus nephritis. Hydroxychloroquine remains a cornerstone of
    pregnancy-compatible lupus nephritis management.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydroxychloroquine
      term:
        id: CHEBI:5801
        label: hydroxychloroquine
  notes: Background antimalarial therapy in SLE; specific antinephritic efficacy not curated with a dedicated trial snippet here.
  evidence:
  - reference: PMID:42420832
    reference_title: "Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hydroxychloroquine and azathioprine remain the cornerstones of pregnancy-compatible LN management."
    explanation: Documents hydroxychloroquine as a safe, pregnancy-compatible cornerstone therapy for lupus nephritis.
- name: Azathioprine Maintenance Therapy
  description: >-
    Azathioprine is a pregnancy-compatible immunosuppressive agent that remains a cornerstone
    of pregnancy-safe lupus nephritis management and can be used as a maintenance therapy option.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: azathioprine
      term:
        id: CHEBI:2948
        label: azathioprine
  evidence:
  - reference: PMID:42420832
    reference_title: "Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hydroxychloroquine and azathioprine remain the cornerstones of pregnancy-compatible LN management."
    explanation: Identifies azathioprine as a cornerstone, pregnancy-compatible immunosuppressive for lupus nephritis.
- name: Calcineurin Inhibition (Tacrolimus)
  description: >-
    Tacrolimus is an acceptable calcineurin inhibitor alternative for pregnancy-compatible
    lupus nephritis management, requiring appropriate therapeutic drug monitoring.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tacrolimus
      term:
        id: CHEBI:61049
        label: tacrolimus (anhydrous)
  evidence:
  - reference: PMID:42420832
    reference_title: "Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Tacrolimus is an acceptable calcineurin inhibitor with appropriate therapeutic drug monitoring."
    explanation: Establishes tacrolimus as a pregnancy-compatible calcineurin inhibitor option for lupus nephritis with drug monitoring.
- name: B Cell Depletion Therapy (Rituximab) — Pregnancy-Cautious Use
  description: >-
    Rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, may be used cautiously
    for life-threatening lupus nephritis during pregnancy, but should be avoided in the
    third trimester due to risk of neonatal B-cell depletion.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  evidence:
  - reference: PMID:42420832
    reference_title: "Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Rituximab may be used cautiously for life-threatening disease, avoiding the third trimester due to neonatal B-cell depletion."
    explanation: Documents rituximab as a cautious, life-threatening-disease-only option in pregnancy, with third-trimester avoidance.
- name: Antiplatelet Therapy for Preeclampsia Prevention
  description: >-
    Low-dose aspirin is recommended universally in lupus nephritis pregnancy management
    to reduce the risk of preeclampsia, a major pregnancy complication in this population.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: acetylsalicylic acid
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
  evidence:
  - reference: PMID:42420832
    reference_title: "Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Low-dose aspirin is recommended universally to reduce preeclampsia risk."
    explanation: Establishes low-dose aspirin as universal preeclampsia prevention in lupus nephritis pregnancies.
discussions:
- discussion_id: gap_kidney_targeted_ln_therapy
  prompt: >-
    Can the intrarenal kidney-immune crosstalk loop be interrupted by kidney-targeted
    therapy without systemic immunosuppression, and does doing so improve renal
    outcomes relative to the current systemic regimens?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Renal Biochemical Niche (Low Oxygen Tension and Hypertonicity)
  - pathophysiology#Intrinsic Renal Cell Antigen Presentation and Cytokine Production
  - pathophysiology#Intrarenal Immune Infiltration and Proinflammatory Cytokine Milieu
  rationale: >-
    Every treatment currently curated on this entry — mycophenolate/cyclophosphamide
    induction, corticosteroids, belimumab, voclosporin, obinutuzumab, rituximab,
    azathioprine — acts systemically, which follows from the unidirectional model in
    which the kidney is a passive target. If the reciprocal arm is a genuine driver,
    the loop is in principle interruptible at renal-restricted nodes (the hypoxic and
    hypertonic niche, renal antigen presentation, renal cytokine production) that
    systemic immunosuppression does not specifically address. The gap is that no
    kidney-targeted agent acting on these nodes has been shown to change renal
    outcomes in patients, so the therapeutic claim remains a prediction of the model
    rather than a curated treatment.
  proposed_experiments:
  - experiment_id: exp_ln_renal_restricted_target_engagement
    name: Renal-restricted target engagement with paired kidney biopsy readouts
    description: >-
      Test an agent directed at a renal-restricted node of the loop (for example
      renal antigen presentation or the hypoxia/hypertonicity response) using paired
      pre- and post-treatment kidney biopsies, scoring change in the intrarenal
      immune infiltrate and local cytokine milieu alongside proteinuric response, and
      comparing against a systemically immunosuppressed control arm to establish
      whether renal-compartment engagement is separable from systemic effect.
  evidence:
  - reference: PMID:39120952
    reference_title: "Lupus Nephritis: Immune Cells and the Kidney Microenvironment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An understanding of these mechanisms can lead to the design of more kidney-targeted treatments and the avoidance of systemic immunosuppressive effects and may represent the next frontier of LN therapies."
    explanation: >-
      Frames kidney-targeted therapy as a prospective consequence of these mechanisms
      ("can lead to", "may represent"), i.e. an open question rather than a
      demonstrated therapeutic result.
review_notes: >-
  Lupus nephritis is curated as a distinct renal manifestation-level entry
  (MONDO:0005556, a manifestation of SLE, MONDO:0007915) separate from the base
  Systemic_Lupus_Erythematosus and Neuropsychiatric_SLE entries. The mechanistic
  chain modeled here (anti-dsDNA/anti-chromatin autoantibodies -> glomerular
  immune-complex deposition -> complement activation and inflammation -> graded
  ISN/RPS glomerular and tubulointerstitial injury) is grounded in the Lech & Anders
  review (PMID:22192660, full text), the Nat Rev Dis Primers primer (PMID:31974366),
  the ISN/RPS classification (PMID:14747370, available in cache for future
  class-level subtyping), and the trigger review on chromatin-directed autoantibodies
  (PMID:42413709). Follow-ups: (1) add ISN/RPS class I-VI as has_subtypes with
  per-class differentiating mechanisms; (2) add hematuria, nephrotic syndrome, and
  hypocomplementemia phenotypes with dedicated quantitative snippets; (3) evaluate
  conforms_to nephrotic_podocyte_injury for the membranous (class V) arm.
datasets:
- accession: geo:GSE306378
  title: Based on single-cell sequencing analysis of CD4+ T cells and B cells in patients with lupus nephritis, the heterogeneity of these cells was investigated.
  description: Utilizing single-cell technology to analyze the heterogeneity of CD4+ T cells and B cells in patients with lupus nephritis.We have delineated the immune cell profile of PBMC in LN patients, and focused on describing the heterogeneity characteristics of CD4+ T cells and B cells. Some specific cell subtypes and ligand-receptor pairs were identified, which indicate potential therapeutic targets for lupus erythematosus.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 6
  publication: PMID:41540405
  notes: Identified by GEO DataSets index search for Lupus Nephritis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE296560
  title: 'Lupus nephritis serum induces changes in gene expression in human glomerular endothelial cells, which is modulated by L-sepiapterin: Implications for redox-mediated endothelial dysfunction'
  description: Lupus nephritis (LN) is characterized by renal endothelial dysfunction, which contributes to progressive kidney injury. Endothelial nitric oxide synthase (eNOS) plays a modulating role in LN, as genetic ablation of the eNOS enzyme worsens disease. Serum from patients with active LN induces uncoupling of eNOS homodimers, leading to superoxide (SO) rather than nitric oxide (NO) production by eNOS. This uncoupling is reversed with L-sepiapterin (L-Sep). This study was designed to further examine changes in gene expression in glomerular endothelial cells induced by LN serum and whether treatment with L-Sep can ameliorate these changes.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 19
  publication: PMID:40480647
  notes: Identified by GEO DataSets index search for Lupus Nephritis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE322527
  title: Single-cell transcriptomes and T cell receptor sequences of CD4 or CD8 single positive T lymphocytes from peripheral blood or urine of lupus nephritis patients at flare.
  description: Proliferative lupus nephritis (LN) is triggered by deposition of autoantibodies in glomeruli and paralleled by a T cell-rich kidney infiltrate. Although these T cells have been attributed with propagation of tissue injury, it is unclear how they are activated and whether T cell autoreactivity drives the local inflammation. Kidney-infiltrating T cells are also observed in urine, where they have high resemblance with interstitial T cells. Therefore, urinary T cells are a proxy to investigate tissue pathogenesis. Here, we analyzed urinary T cells to elucidate if a kidney-specific T cell autoimmune reaction contributes to tubulointerstitial inflammation in LN.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 26
  notes: Identified by GEO DataSets index search for Lupus Nephritis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001007117
  title: Identification of Long Non-coding RNA Biomarker of Human Lupus Nephritis Disease Activity
  description: Total RNA sequencing was performed on whole blood samples from 74 Lupus nephritis (LN) patients and 20 healthy controls. Differential expression analysis and weighted gene co-expression network analysis were performed to characterise expression changes of long non-coding RNAs (lncRNAs) in LN and identify lncRNAs with a key role in disease activity that could be used as potential blood-based biomarkers.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Lupus Nephritis"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS50000000159
  title: ScRNA-seq of human kidney immune cells of patients with ANCA-associated glomerulonephritis, Lupus Nephritis against a "healthy" nephrectomy control
  description: ANCA-associated glomerulonephritis (AGN) associates with a high risk of end-stage kidney disease. The role of kidney immune cells in local inflammation remains unclear. Here, we investigate kidney immune cell diversity and function. Kidney tissue from AGN patients (n=5) and a lupus nephritis (LN) patient (n=1) were aquired during a biopsy procedure for a clinical indication. Needle-core biopsies were obtained for histopathological examination, and an additional pass was performed to retrieve kidney tissue for scRNA-seq. Healthy kidney tissue (n=1) was obtained from a kidney that was surgically removed do tue due to a (non-invasive) papillary urothelial carcinoma.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Lupus Nephritis"); description-level mentions were not accepted. EGA study_type: RNASeq. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: dbgap:phs001609
  title: Genetic Contributions of Lupus Nephritis in A Multi-Ethnic Cohort
  description:  Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) and it occurs at a much higher rate in patients that are not of European descent. The purpose of this study is to identify genetic variants contributing to the risk of LN in a multi-ethnic cohort of SLE patients. We used a comprehensive genome-wide screen and 1244 SLE patients from 5 different ethnic groups. In genome-wide gene-based and candidate SNP analyses, we found distinct genes and pathways, and established risk SNPs associated with lupus nephritis for each ethnic group.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Lupus Nephritis"). Retrieved 2026-08-02.
📚

References & Deep Research

Deep Research

1
Claude Code ▸
1. Disease Information
claude-haiku-4-5-20251001, claude-sonnet-5 126 citations 2026-07-26T13:27:36.263368

1. Disease Information

Overview: Lupus nephritis (LN) is immune complex–mediated glomerulonephritis occurring as an organ-specific manifestation of systemic lupus erythematosus (SLE), affecting an estimated 30–60% of adult SLE patients and up to 70–80% of childhood-onset SLE patients over the disease course. It results from deposition of autoantibody–autoantigen immune complexes (chiefly anti-dsDNA/chromatin-containing complexes) in the glomerular mesangium, subendothelial and/or subepithelial space, triggering complement activation, leukocyte recruitment, and progressive glomerular, tubulointerstitial, and vascular injury. Renal involvement is one of the strongest predictors of morbidity and mortality in SLE and is the only organ-specific finding (biopsy-proven class III/IV LN) sufficient on its own, together with a positive ANA, to classify a patient as having SLE under the 2019 EULAR/ACR criteria (renal biopsy with class III or IV LN plus ANA ≥1:80 meets the ≥10-point classification threshold) Rheumatology Advisor.

Key identifiers: - MONDO: MONDO:0005556 Wikidata - Parent disease (SLE) OMIM: #152700 — Systemic Lupus Erythematosus OMIM (no LN-specific OMIM entry exists; LN is coded as an SLE manifestation) - ICD-10-CM: M32.14 (Glomerular disease in systemic lupus erythematosus); M32.15 (Tubulo-interstitial nephropathy in SLE); N08.5 (glomerular disorders in other systemic connective tissue disorders, when secondary coding is used) ICD10Data - Orphanet: No LN-specific ORPHA code exists; Orphanet aggregates all SLE organ manifestations under ORPHA:536 (Systemic lupus erythematosus); pediatric-onset SLE is separately coded ORPHA:93552 Orphanet - MeSH: D008181 (Lupus Nephritis) - GARD/NIH Rare Disease entry: GARD 10747 GARD

Notably, a 2026 NDT commentary argues that active/refractory lupus nephritis functionally behaves as an orphan disease given its rarity in clinical trials and limited approved-therapy landscape, despite lacking formal orphan designation NDT.

Synonyms: SLE nephritis, lupus glomerulonephritis, LGN. Data underlying this report derive from aggregated disease-level resources (case series, registries, RCTs, GWAS meta-analyses) rather than individual EHR records, except where explicitly noted (e.g., single-institution biomarker cohorts).

2. Etiology

Causal/risk factors — genetic

LN susceptibility is polygenic, shaped by common variants shared with SLE plus a smaller set of loci with LN-specific effect enrichment, and rare high-penetrance monogenic causes account for a minority of cases.

  • HLA region (chr 6p21): Class II HLA alleles (e.g., HLA-DR2, DR3) are the strongest common SLE/LN susceptibility signals; GWAS of 2,000 unrelated European-ancestry women with SLE (588 with LN vs 1,412 without) identified nephritis-enriched MHC and non-MHC signals PMC3135416.
  • STAT4: SNP rs7582694 and linked variants show genome-wide-significant association with LN specifically (OR ~2.0–2.2, p as low as 3.76×10⁻²⁹ in case-control analysis) and with severe renal insufficiency in case-only analyses (OR 2.22, p=1.6×10⁻³) PMC3873995, PLOS ONE.
  • IRF5: Two near-perfectly linked SNPs (rs2070197, rs10488631; r²≈1.0) show strong LN association (p<1×10⁻⁴) PMC8123735.
  • ITGAM/ITGAX (CD11b/CD11c, chr16): Confirmed SLE/LN susceptibility locus from the landmark NEJM 2008 GWAS alongside BLK–C8orf13 NEJM.
  • PXK, BLK, TNIP1, CARD11, IRAK1, PMS2: Additional SNPs implicated in LN risk across case series; PXK is also a shared IgA nephropathy/SLE susceptibility gene (p=3.62×10⁻²⁴), suggesting convergent glomerular-injury pathways PMC5090199.
  • Multi-ancestry GWAS meta-analysis (2023): Cross-population SLE risk-score models now inform clinical risk prediction, relevant to LN given the strong genetic overlap Nature Communications.

Rare, high-penetrance monogenic causes (~1–2% of SLE/LN cases collectively): - Complete C1q deficiency: >90% of individuals develop SLE or lupus-like disease; C1q-deficient patients present predominantly with cutaneous and renal involvement, and C1q gene SNPs specifically associate with LN in African American and Hispanic populations PMC5186770, PMC3467517. - C2, C4A, C4B complete deficiency: Classical-pathway deficiencies impair immune-complex clearance, promoting SLE/LN. - C1s deficiency: Documented case report of SLE with renal involvement in a male patient PMC10925646. - TREX1 mutations: ~0.5–3% of SLE patients carry TREX1 mutations (3′ repair exonuclease 1; loss of function causes accumulation of endogenous nucleic acids triggering cGAS-STING/type I interferon activation, linking TREX1-related SLE to the Aicardi-Goutières spectrum) PMC3135416.

Environmental risk factors

  • Sex: Female predominance (SLE overall ~9:1 F:M), though male sex is a poor-prognosis marker specifically within LN cohorts (below).
  • Ancestry/race: Non-European ancestry (Black, Hispanic, Asian, Indigenous) is the single strongest non-genetic-mechanistic risk modifier for LN development and severity (Section 9).
  • UV/photosensitivity: Established SLE trigger; experimental models show UV-induced NETosis driving skin-and-kidney inflammatory flares.
  • Infections, smoking, silica exposure, certain drugs (hydralazine, procainamide — drug-induced lupus, generally without nephritis): Established broader SLE environmental risk factors.

Protective factors

Well-powered genetic/environmental protective-factor data specific to LN (as opposed to SLE broadly) are limited in the literature surveyed; no robust LN-specific protective allele or lifestyle factor emerged in this search. This is a notable knowledge gap worth flagging as KNOWLEDGE_GAP in the KB entry.

Gene-environment interactions

UV exposure interacting with IFN-pathway risk alleles, and infection/complement-deficiency interactions impairing apoptotic-debris clearance, are the best-characterized GxE mechanisms, though LN-specific quantitative GxE studies were not identified in this literature pass beyond the general SLE literature.

3. Phenotypes

Suggested HPO terms and characteristics (renal-focused; broader SLE phenotypes such as malar rash, arthritis are typically modeled on the parent SLE entry rather than duplicated here):

Phenotype HPO term Notes
Proteinuria HP:0000093 Hallmark presenting sign; nephrotic-range proteinuria in membranous (Class V) and diffuse proliferative (Class IV) disease
Nephrotic syndrome HP:0000100 Occurs especially in Class V and mixed III/IV+V
Hematuria HP:0000790 Microscopic common; gross hematuria less common
Glomerulonephritis HP:0000099 Umbrella histopathologic finding
Hypertension HP:0000822 Common at diagnosis and with CKD progression
Renal insufficiency / Stage 5 chronic kidney disease HP:0003774 / HP:0003774-adjacent (CKD) Progressive in undertreated/refractory disease
Elevated circulating antinuclear antibody level HP:0033195 Serologic biomarker
Reduced circulating complement C3/C4 HP:0045081 (hypocomplementemia)/ related Classic activity marker, though imperfect (Section 6/10)
Edema HP:0000969 Secondary to nephrotic syndrome
Acute kidney injury HP:0001919 In rapidly progressive/crescentic presentations

Onset/characteristics: LN most commonly manifests within the first 1–3 years after SLE diagnosis (childhood-onset SLE has a markedly higher cumulative LN incidence — up to 70–80% — than adult-onset, ~30–60%). Severity and course are variable: Class III/IV (proliferative) disease is typically acute-to-subacute with active urinary sediment and rapid GFR decline if untreated; Class V (membranous) is more indolent, dominated by nephrotic-range proteinuria; mixed III/IV+V combines both patterns. Course can be relapsing-remitting (flares interspersed with remission) or progressive to CKD/ESRD despite therapy in 10–30% of severe cases within 15 years PMC12565261.

QoL impact: Nephrotic syndrome, CKD progression, dialysis dependence, and the cumulative toxicity of long-term immunosuppression (infection risk, glucocorticoid morbidity, infertility risk with cyclophosphamide) substantially affect quality of life; pediatric-onset disease carries additional psychosocial and growth/development burden.

4. Genetic/Molecular Information

Covered largely under Etiology (Section 2). Summary for KB gene annotation purposes:

Gene HGNC Role Variant type
STAT4 hgnc:11365 Th1 differentiation, IFN-γ signaling Common intronic risk SNPs (rs7582694 and linked)
IRF5 hgnc:6119 Type I IFN pathway transcription factor Common risk SNPs (rs2070197, rs10488631)
ITGAM (CD11b) hgnc:6149 Complement receptor 3 subunit; leukocyte adhesion/phagocytosis Common coding/regulatory risk variants
BLK hgnc:1057 B-cell receptor signaling (B lymphoid kinase) C8orf13-BLK locus risk variants
PXK hgnc:24500 Endocytic trafficking Risk SNP shared with IgA nephropathy
C1QA/B/C hgnc:1241/1242/1243 Classical complement pathway initiation Complete deficiency (rare, high penetrance)
C2 hgnc:1248 Classical complement pathway Complete deficiency
C4A/C4B hgnc:1234/1235 Classical complement pathway, immune complex clearance Complete deficiency; copy-number variation
TREX1 hgnc:12269 3′→5′ DNA exonuclease; suppresses cGAS-STING activation Loss-of-function mutations

Functional consequences: Complement-pathway loss-of-function → impaired clearance of apoptotic debris/immune complexes → chronic autoantigen exposure. TREX1 loss-of-function → cytosolic ssDNA/dsDNA accumulation → cGAS-STING-driven type I interferon production. STAT4/IRF5 gain-of-risk-allele effects amplify Th1/IFN signaling, intensifying renal inflammatory infiltration.

Somatic vs germline: LN genetic risk is essentially entirely germline; no somatic mosaicism/clonal mechanism is established.

Epigenetics: DNA hypomethylation of IFN-response genes in T cells is a well-described SLE epigenetic signature (broader SLE literature); LN-specific epigenetic/DiseaseMeth data were not surfaced in this pass and represent a further gap to verify with a dedicated search of ENCODE/DiseaseMeth if curating an epigenetics subsection.

5. Environmental Information

  • UV radiation: Established trigger for cutaneous and systemic flares, mechanistically linked to keratinocyte apoptosis, autoantigen exposure, and NETosis-driven flares affecting both skin and kidney in murine models [bioRxiv preprint noted above].
  • Infections: Viral (EBV) and bacterial triggers implicated in broader SLE pathogenesis via molecular mimicry and bystander immune activation; no LN-specific infectious trigger was identified as distinct from general SLE literature in this search pass.
  • Smoking, silica, and occupational/toxin exposures: Established general SLE risk factors; specific LN-stratified toxicological data were not located in this pass (a CTD/TOXNET-focused follow-up search would be needed for LN-specific quantification).
  • Socioeconomic/structural factors: Poverty, healthcare access disparities, and discrimination are explicitly implicated as contributors — independent of genetics — to worse LN outcomes in non-White populations Duke Scholars, ScienceDirect Disparities.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream)

  1. Loss of immune tolerance / autoantibody generation (upstream, systemic): Genetic susceptibility (HLA, STAT4, IRF5, complement/TREX1 lesions) plus environmental triggers (UV, infection) drive loss of B-cell tolerance to nuclear antigens. Autoreactive B cells differentiate into long-lived plasma cells producing sustained anti-dsDNA and anti-nucleosome antibodies; CD4+ Th1/Th17 cells provide help and amplify inflammatory cytokine production BMC Nephrology.
  2. Immune complex formation and glomerular deposition (organ-entry point): Circulating and in situ–formed immune complexes (anti-dsDNA/chromatin bound to glomerular basement membrane components) deposit in mesangial, subendothelial, and/or subepithelial compartments, determining the ISN/RPS histologic class.
  3. Complement activation (amplification): Immune complexes engage C1q, activating the classical pathway; the alternative pathway amplification loop further boosts complement deposition. Terminal complement components (C5a, C5b-9/MAC) trigger acute cellular inflammatory responses via cytokine/interleukin signaling cascades. Emerging work also describes noncanonical intracellular complement functions regulating immune-cell metabolism ScienceDirect Complement Review 2025.
  4. Type I interferon (IFN-I) pathway activation: IFN-I transcripts are overexpressed in renal biopsy tissue from proliferative LN, with elevated neutrophil-derived defensin-α3 transcripts implicating neutrophil extracellular traps (NETs) as a local IFN-I driver within the kidney Rheumatology (Oxford) PMID:36355567. NETs also promote further complement activation and autoantigen exposure, creating a self-amplifying inflammatory loop.
  5. Cellular infiltration and injury: CD4+ T cells (Th1/Th17), infiltrating B cells (including an age-associated B-cell subset identified by scRNA-seq), monocyte/macrophage populations at progressive differentiation stages, and neutrophils accumulate in the kidney interstitium and glomeruli, producing pro-inflammatory cytokines, ROS, and proteolytic enzymes Nature Immunology PMID (AMP consortium).
  6. Podocyte and tubular epithelial injury: Podocyte foot-process effacement and podocyte loss (nephrin loss demonstrated in NZM2410 mice) drive proteinuria; sustained proteinuria and ischemia further injure podocytes and tubular epithelium, and podocyte–tubular epithelial–immune cell crosstalk sustains chronicity Frontiers in Immunology 2025.
  7. Chronic tissue remodeling / fibrosis (downstream, irreversible endpoint): Interstitial fibrosis and tubular atrophy (captured by the ISN/RPS chronicity index) mark irreversible nephron loss, culminating in progressive CKD/ESRD in a subset of patients.

Cell types (CL terms)

  • Glomerular podocyte — CL:1000452 (or CL:0000653 podocyte)
  • Mesangial cell — CL:0000650
  • Glomerular endothelial cell — CL:1000450
  • Plasma cell — CL:0000786
  • Age-associated B cell subset (ABC) — CL:0000236 (B cell, more specific subset term not formally in CL)
  • Th1/Th17 CD4+ T cell — CL:0000545 / CL:0000899
  • Neutrophil — CL:0000775
  • Monocyte/macrophage (kidney-infiltrating) — CL:0000576/CL:0000235
  • Renal tubular epithelial cell — CL:1001285 or CL:0002518

Biological processes (GO terms)

  • Complement activation, classical pathway — GO:0006958
  • Complement activation, alternative pathway — GO:0006957
  • Type I interferon signaling pathway — GO:0060337
  • Neutrophil extracellular trap formation — GO:0140448 (NETosis)
  • Immune complex clearance/response — GO:0002455 (Fc-receptor mediated immune complex signaling context)
  • Podocyte apoptotic process — GO:1990009 (renal podocyte process)
  • Renal fibrosis / response to injury — GO:0072028 (renal tubule morphogenesis) or fibrosis-related GO terms

Molecular profiling

  • Transcriptomics: The 2019 AMP (Accelerating Medicines Partnership) SLE Network scRNA-seq studies produced the first comprehensive human LN kidney immune-cell atlas (21 leukocyte subsets) Nature Immunology; murine transcriptomic comparisons across MRL/lpr, NZB/W, and BXSB/Yaa reveal both unique and shared regulatory networks PLOS ONE PMC3805607.
  • Spatial transcriptomics: Childhood-onset LN spatial profiling reveals complex kidney stroma–immune cell interactions, addressing the spatial-information loss inherent to dissociative scRNA-seq PMC10680641; murine imiquimod-induced LN spatial transcriptomics elucidates renal fibrosis mechanisms ScienceDirect 2025.
  • mTOR pathway: Cross-species mapping shows shared mTOR pathway perturbations between mouse LN models and human LN PMC2656226.

Immune system involvement

LN is fundamentally an autoimmune/immune-complex disease combining humoral autoimmunity (autoantibody/immune complex formation), complement-mediated tissue injury, and cell-mediated (T cell, NET-driven) inflammation — a multi-arm immunopathology rather than a single-pathway process.

7. Anatomical Structures Affected

  • Primary organ: Kidney (UBERON:0002113), specifically the renal glomerulus (UBERON:0000074), renal cortex, and tubulointerstitium (UBERON:0001225/renal tubule).
  • Secondary/systemic involvement: As an SLE manifestation, LN co-occurs with skin (malar rash, discoid lesions), joints (arthritis), serosa (pleuritis, pericarditis), CNS (neuropsychiatric lupus), and hematologic (cytopenias) involvement — modeled on the parent SLE entry.
  • Cell/tissue level: Glomerular basement membrane (immune complex deposition site), mesangium, glomerular capillary endothelium, podocytes (visceral epithelial cells), tubular epithelium, peritubular capillaries, and renal vasculature (lupus vasculopathy/vasculitis in some cases).
  • Subcellular: Glomerular basement membrane (extracellular matrix compartment); podocyte foot processes/slit diaphragm (GO Cellular Component: GO:0097610 filtration slit); mitochondria and cytosol relevant to TREX1/cGAS-STING nucleic-acid-sensing pathway.
  • Localization/laterality: Bilateral, diffuse (typically both kidneys symmetrically involved; focal vs diffuse relates to the proportion of glomeruli affected per the ISN/RPS classification, not laterality between kidneys).

8. Temporal Development

  • Onset: Can occur at any SLE disease stage but most often within the first few years after SLE diagnosis; can rarely be the presenting SLE manifestation. Onset pattern ranges from insidious (Class V/membranous) to acute/rapidly progressive (crescentic Class IV).
  • Staging (histologic, ISN/RPS 2018): Class I (minimal mesangial), Class II (mesangial proliferative), Class III (focal, <50% glomeruli), Class IV (diffuse, ≥50% glomeruli; segmental IV-S or global IV-G), Class V (membranous), Class VI (advanced sclerosing, ≥90% globally sclerosed glomeruli). The 2018 revision replaced subclasses A/C/A+C with NIH-derived activity index (AI) and chronicity index (CI) semiquantitative scores, emphasizing tubulointerstitial lesions; interstitial inflammation within this framework independently predicts renal outcome PMC10085727, PubMed 33682052.
  • Progression rate/course: Variable — relapsing-remitting is common; 10–30% of severe LN progresses to ESRD within 15 years despite aggressive immunosuppression PMC12565261. In pediatric-onset severe LN, patients who progress to ESRD reach CKD stage 3 at a median of 3.2 years post-diagnosis, versus 8 years for the overall severe-LN cohort PMC11985274.
  • Remission patterns: Complete/partial renal response is the standard trial endpoint (proteinuria reduction, stable/improved eGFR); remission can be treatment-induced (rarely spontaneous) and is a key predictor of long-term renal survival — failure to achieve remission by 12 months predicts advanced CKD in pediatric cohorts.
  • Critical periods: Early, aggressive induction therapy within the first weeks-to-months of active proliferative disease is considered the critical intervention window to prevent irreversible glomerulosclerosis/fibrosis.

9. Inheritance and Population

Epidemiology

  • LN prevalence among people with SLE is markedly race/ethnicity-stratified: 53.2% in Asian, 50.7% in Black, 49.4% in Hispanic, vs 25.4% in White SLE patients MyLupusTeam summary of literature.
  • Population-level LN prevalence per 100,000: African American 59.69, Asian 56.56, Hispanic 29.84, White 15.83 ScienceDirect African American disparities.
  • Hazard ratios for developing LN after SLE diagnosis (vs. White): African American HR 2.3, Asian HR 4.3, Hispanic HR 2.4.
  • Progression to kidney failure is ~9-fold greater in African American vs White patients with LN.

Inheritance pattern

LN/SLE is multifactorial/polygenic for the vast majority of patients (not classic Mendelian), with rare autosomal recessive monogenic forms (complete complement component deficiencies — C1q, C2, C4 — and TREX1-related interferonopathy) that can behave in a near-Mendelian, highly penetrant fashion (>90% penetrance for complete C1q deficiency). No AD, X-linked, or mitochondrial inheritance pattern is established for LN specifically. Genetic anticipation, founder effects specific to LN (as distinct from SLE broadly), and consanguinity data were not surfaced in this literature pass — appropriate to flag as a further gap if precise quantification is needed for the KB Inheritance block.

Demographics

  • Sex ratio: Female predominant, consistent with SLE overall (~9:1).
  • Age distribution: Peaks in women of reproductive age (child-bearing years); childhood-onset (pediatric) LN carries a worse prognosis than adult-onset, and disease onset in advanced age also shows distinct (generally milder but comorbidity-complicated) outcomes per pediatric-vs-adult-vs-advanced-age-onset comparative studies PMC11966454.
  • Geographic distribution: Global; highest burden aligns with populations of African, Asian, and Hispanic/Indigenous ancestry regardless of geography, consistent with genetic-ancestry-linked risk rather than a purely geographic/endemic pattern.

10. Diagnostics

Clinical tests

  • Urinalysis/urine sediment: Active sediment (dysmorphic RBCs, RBC casts, cellular casts) signals proliferative disease activity.
  • Proteinuria quantification: Urine protein:creatinine ratio (UPCR) is the standard quantitative/trial endpoint measure.
  • Serologic biomarkers: Anti-dsDNA antibody titer and complement C3/C4 are the conventional activity markers with the strongest clinical evidence base, though only moderate discriminative performance for predicting LN, flares, and treatment response PMC12565261.
  • Novel urinary biomarkers (outperforming conventional markers in several cohorts):
  • ALCAM (activated leukocyte cell adhesion molecule): AUC 0.75–0.83 for renal/SLE disease activity, best cSLE discriminator in Bayesian network analysis PMC7251704, PMC9204340.
  • VCAM-1: AUC 0.77–0.88.
  • MCP-1 (CCL2): AUC 0.79 PMC12088007.
  • PF4, hemopexin, sCD163, CXCL10, NGAL, TWEAK, uric acid: Additional candidates with good LN-vs-non-renal-SLE discriminative ability.
  • Neuropilin-1 (urinary): Predictive of renal outcome PMC6769814.
  • Complement fixed/functional assays and non-canonical complement markers: anti-C1q, anti-ficolin, anti-C1s antibodies, and tissue-based renal C4d and C5b-9 deposits are discussed as improved activity/prognosis markers beyond CH50/C3/C4 ScienceDirect Complement 2025.
  • Renal biopsy (definitive diagnostic test): Required for ISN/RPS histologic classification, activity/chronicity index scoring, and to distinguish LN from other glomerulopathies. Full-house immunofluorescence staining (IgG, IgA, IgM, C3, C1q, kappa, lambda all positive) with strong C1q staining is characteristic of LN and helps distinguish it from other glomerulonephritides PMC11640231.

Genetic testing

Not routinely used for diagnosis of typical polygenic LN; targeted complement pathway (C1q, C2, C4) and TREX1 testing may be considered in atypical presentations (very early onset, family history, disproportionate cutaneous/renal phenotype) suggestive of monogenic lupus/interferonopathy.

Clinical/classification criteria

  • 2019 EULAR/ACR SLE classification criteria: Entry criterion = ANA ≥1:80; renal biopsy showing Class III/IV LN contributes 10 points (Class II/V contributes 8 points), sufficient alone (with positive ANA) to classify SLE. High sensitivity for LN-containing SLE cohorts; the criteria's renal-domain weighting reaffirms the centrality of biopsy Rheumatology Advisor; the 2019 score also predicts subsequent renal flare risk Renal and Urology News.
  • ISN/RPS 2018 histopathologic classification (Section 8) is the diagnostic/prognostic gold standard once biopsy is obtained.

Screening

No population-level newborn or carrier screening applies (LN is not classically Mendelian); however, all SLE patients are recommended for periodic urinalysis/proteinuria screening to detect subclinical renal involvement early, and biopsy is recommended for any SLE patient with new proteinuria (typically UPCR threshold ≥0.5 g/g) or active urinary sediment per KDIGO guidance.

11. Outcome/Prognosis

  • ESRD risk: 10–30% of severe LN patients progress to ESRD within 15 years despite modern immunosuppressive therapy PMC12565261.
  • Pediatric-specific: In one severe-LN cohort, 28/95 (≈29%) progressed to ESRD; those progressing reached CKD stage 3 at a median 3.2 years post-diagnosis vs 8 years for the overall cohort; 14.8% developed advanced CKD at last follow-up PMC11985274. Childhood-onset LN carries a worse renal prognosis than adult-onset disease, though outcomes have improved substantially over three decades of evolving therapy Springer/CJASN PMID 21799148.
  • Prognostic risk factors: Rapidly progressive glomerulonephritis, non-response to induction treatment, severe kidney flare, male sex, failure to achieve remission by 12 months, hypertension, neurologic involvement, treatment non-compliance, and lower eGFR at diagnosis all predict adverse kidney outcomes in pediatric cohorts PMC11985274; serositis is a broader marker of poor pediatric SLE prognosis PMC11959889.
  • Renal vascular lesions (a distinct pathologic feature beyond the standard ISN/RPS glomerular classes) are recognized as an independent contributor to poor outcomes in childhood-onset LN PMC11584461.
  • Race disparities in mortality: Black patients with SLE/LN are more likely to die of the disease, and the average age of SLE-related death is significantly younger in Black patients than White patients PMC11815449.
  • Pregnancy-related outcome data: Preeclampsia occurs in 25.7% of LN pregnancies vs 2.9% of non-renal-lupus pregnancies; preterm birth (<37 weeks) in 25.7% vs 7.5%; preeclampsia occurred in 66.7% of preterm LN deliveries PMC8120629. History of renal flare, hypertension, and longer disease duration predict preeclampsia/HELLP; adverse maternal outcomes are often reversible with prompt diagnosis/treatment Kidney Medicine.

12. Treatment

Pharmacotherapy — approved agents (with MAXO/therapeutic-agent mapping guidance)

Three drugs are now FDA-approved specifically for lupus nephritis (in addition to background mycophenolate/cyclophosphamide + glucocorticoid standard-of-care), reflecting rapid label expansion 2020–2025:

  1. Belimumab (2020 approval) — anti-BAFF/BLyS monoclonal antibody (therapeutic_modality: MONOCLONAL_ANTIBODY; NCIT drug-class term available). BLISS-LN trial (NEJM 2020;383(12):1117-1128, PMID available via DOI 10.1056/NEJMoa2001180): phase 3, 104-week, RCT of belimumab 10 mg/kg + standard therapy vs standard therapy alone in 448 patients across 107 sites/21 countries; belimumab arm had significantly higher primary efficacy renal response rate NEJM. Post-hoc analyses show belimumab most effective in proliferative LN with baseline UPCR <3 g/g, reducing risk of renal events/death and LN flare Kidney International.
  2. Voclosporin (LUPKYNIS, 2021 approval) — calcineurin inhibitor (CNI) (therapeutic_modality: SMALL_MOLECULE). AURORA 1 trial (Lancet 2021;397(10289):2070-2080, PMID:33971155): phase 3, 142 sites/27 countries, patients with biopsy-proven Class III/IV (±V) LN; voclosporin + MMF + low-dose steroids achieved a clinically/statistically superior complete renal response vs MMF + low-dose steroids alone, comparable safety, most common AEs infections (pneumonia most serious) ScienceDirect/Lancet.
  3. Obinutuzumab (2025 approval — third-ever LN-specific drug) — type II anti-CD20 monoclonal antibody (therapeutic_modality: MONOCLONAL_ANTIBODY). REGENCY trial: complete renal response at 76 weeks in 46.4% (obinutuzumab, n=135) vs 33.1% (placebo, n=136), all patients on background MMF + oral prednisone (target 5 mg/d by week 24) Medscape; post hoc analysis in Arthritis & Rheumatology 2024 confirms preserved kidney function/outcomes Wiley A&R.

Investigational / emerging

  • Anifrolumab (anti-type I IFN receptor mAb, SAPHNELO): Phase 2 TULIP-LN trial (147 randomized) tested an intensified regimen (900 mg IV ×3 then 300 mg) vs basic regimen vs placebo; intensified regimen showed higher complete renal response through Year 2 extension (PMID:37607780) PubMed. An optimized, longer intensified dosing regimen (6× 900 mg Q4W then 300 mg) was selected for the ongoing Phase 3 IRIS trial (NCT05138133), estimated primary completion 2027 ClinicalTrials.gov; dose-selection rationale published 2026 in Clinical Pharmacology & Therapeutics Wiley CPT.
  • Complement inhibitors: Ravulizumab (anti-C5) and ALXN2050 (alternative-pathway factor D inhibitor) are in trials for proliferative LN/IgA nephropathy ClinicalTrials.gov NCT04564339, NCT05097989.
  • CAR-T cell therapy (rapidly emerging, 2024–2025): Autologous and allogeneic anti-CD19 CAR-T therapy achieves deep peripheral and renal B-cell depletion and durable clinical remission in refractory SLE/LN case series — e.g., a Cleveland Clinic LN patient in drug-free remission >1 year post-infusion Cleveland Clinic; allogeneic CD19 CAR-T achieved durable remission with no GvHD/CRS/ICANS in a small cohort (PMID:40446794) PubMed; CTA313 (dual CD19/BCMA-targeting, depleting both autoreactive B cells and long-lived plasma cells) showed early efficacy signals in a 7-patient trial Frontiers 2024. Dedicated CD19/BCMA CAR-T trials for refractory/relapsed LN are recruiting (NCT06785519, NCT06681337) ClinicalTrials.gov.
  • Combination/triple therapy trial: PRESERVE trial (NCT07611214) testing voclosporin + belimumab, obinutuzumab, or anifrolumab combinations for rapid renal response ClinicalTrials.gov.

Guideline-based treatment strategy

KDIGO 2024 Clinical Practice Guideline (focused update of KDIGO 2021 glomerular diseases guideline, published Kidney International supplements, January 2024) KDIGO PDF: - Active Class III/IV LN (±membranous component) should be treated initially with glucocorticoids plus one of: MMF, MMF+belimumab, MMF+CNI (including voclosporin), or cyclophosphamide. - Triple immunosuppressive regimens (MMF + belimumab or CNI, added to standard therapy) are recommended particularly for patients with poor prognostic factors and severe proteinuria, given the rapid proteinuria reduction seen with CNIs; patients responding to triple induction can continue triple regimens into maintenance. - EULAR guidance has incorporated MMF + obinutuzumab as an additional initial-treatment option following REGENCY data Renal & Urology summary of recent advances.

MAXO term suggestions

  • MAXO:0000647 chemotherapy (cyclophosphamide induction)
  • NCIT:C15986 Pharmacotherapy (paired with therapeutic_agent for belimumab, voclosporin, obinutuzumab, anifrolumab, mycophenolate, glucocorticoids)
  • MAXO:0010039 organ transplantation (kidney transplant for ESRD)
  • MAXO:0000950 supportive care (RAAS blockade/antihypertensives for proteinuria/hypertension management, hydroxychloroquine as background SLE therapy)

13. Prevention

  • Primary prevention: No disease-specific primary prevention exists for LN itself; general SLE risk-reduction advice (UV protection/sun avoidance, smoking cessation) is the closest analog, extrapolated from broader SLE literature.
  • Secondary prevention (early detection): Routine urinalysis/proteinuria screening in all SLE patients to catch subclinical renal involvement before irreversible damage; low threshold for renal biopsy with new proteinuria or active sediment.
  • Tertiary prevention: Hydroxychloroquine background therapy (reduces flare frequency/renal flare risk across SLE), RAAS blockade (ACEi/ARB) for proteinuria reduction and nephroprotection, aggressive blood pressure control, and vaccination/infection-prophylaxis given long-term immunosuppression burden.
  • Pregnancy planning/counseling: Given the markedly elevated preeclampsia/preterm-birth risk in LN pregnancies, preconception counseling emphasizing disease quiescence (≥6 months remission recommended before conception in general SLE/LN practice) and close obstetric-rheumatology co-management is a key preventive strategy Kidney Medicine.
  • Genetic counseling: Relevant primarily in rare monogenic complement-deficiency or TREX1-related interferonopathy presentations, where family screening may be considered.

14. Other Species / Natural Disease

Spontaneous natural LN-like disease in domestic animals is not well-characterized as a distinct veterinary entity in the literature surveyed (unlike, e.g., canine SLE-like syndromes reported anecdotally in veterinary case series); this represents a gap relative to OMIA/veterinary-database cross-referencing that was not resolved in this search pass. The primary cross-species relevance of LN is via engineered/spontaneous murine models (below), not naturally occurring disease in companion or wild species.

15. Model Organisms

Murine models are the dominant and best-validated model system for LN mechanistic and preclinical therapeutic research:

  • NZB/W F1 (New Zealand Black × New Zealand White) and derivative substrains NZM2410, NZM 2328: Classic spontaneous lupus nephritis models with high circulating type I IFN, autoantibody production, and lupus nephritis; NZM2410 mice show podocyte nephrin loss, directly recapitulating human podocyte injury PLOS ONE.
  • MRL/lpr (Fas-signaling-deficient): Spontaneous, accelerated lupus-like disease with lymphoproliferation and nephritis; IFN-inducible gene upregulation correlates with disease progression, though the causal role of IFN-α in this strain remains controversial/unresolved (a candidate HUMAN_MODEL_MISMATCH consideration for KB curation) Nature Scientific Reports.
  • BXSB/Yaa: Y-chromosome-linked autoimmune acceleration (duplicated TLR7 locus) driving male-predominant severe lupus nephritis (notably reversing the usual female-predominant sex bias, a distinctive model feature).
  • IFN-α-accelerated NZB/W model: Exogenous IFN-α administration synchronizes onset and accelerates progression, useful for shortened preclinical study timelines; blood transcriptome analysis of this accelerated model shows interferon, plasma cell, neutrophil, T-cell, and protein-synthesis signatures mirroring human disease [PMC5070861 context / general model literature].
  • Pristane-induced (SWR×NZB) F1 model: Produces prominent tubulointerstitial inflammation and fibrosis closely resembling human LN-like fibrotic patterns, useful specifically for studying the chronic/fibrotic endpoint of LN PMC5070861.
  • Imiquimod-induced (TLR7 agonist) model: Inducible model recently profiled by single-cell spatial transcriptomics to dissect renal fibrosis mechanisms ScienceDirect 2025.
  • AAV (adeno-associated virus)-induced LN models: Newer inducible/engineered approach for generating lupus nephritis phenotypes in mice with more controlled onset kinetics Inotiv.
  • Cross-model transcriptomic comparison: Comparative profiling across three murine LN models reveals both shared (core inflammatory/IFN) and model-specific regulatory networks, informing which findings are likely to generalize to human disease vs. being strain-idiosyncratic PLOS ONE / PMC3805607; shared mTOR pathway perturbations between mouse models and human LN have also been mapped directly PMC2656226.

Model limitations: No single murine model fully recapitulates the human ISN/RPS histologic spectrum, the race/ethnicity-linked severity disparities, or human-specific complement/HLA haplotype effects — a translational caveat worth flagging (HUMAN_MODEL_MISMATCH) especially for IFN-α's causal-vs-correlative role in MRL/lpr disease and for any claim extrapolating murine podocyte/fibrosis mechanisms directly to human treatment response without confirmatory human kidney biopsy/spatial-transcriptomic data.

Summary Table: Suggested Evidence Anchors for KB Curation

Claim PMID/Reference Evidence type
BLISS-LN belimumab efficacy NEJM 2020;383(12):1117-1128 (DOI 10.1056/NEJMoa2001180) HUMAN_CLINICAL
AURORA 1 voclosporin efficacy PMID:33971155 (Lancet 2021;397:2070-2080) HUMAN_CLINICAL
REGENCY obinutuzumab efficacy Arthritis & Rheumatology 2024, DOI 10.1002/art.42734 HUMAN_CLINICAL
TULIP-LN anifrolumab Year 2 extension PMID:37607780 HUMAN_CLINICAL
STAT4 renal insufficiency association PMC3873995 / PLOS ONE PMID (rs7582694) HUMAN_CLINICAL (genetic)
C1q deficiency SLE/LN penetrance PMC5186770 HUMAN_CLINICAL (genetic)
ITGAM/BLK GWAS NEJM 2008 (PMID:18768667, NEJMoa0707865) HUMAN_CLINICAL (genetic)
Type I IFN/neutrophil transcripts in LN biopsy PMID:36355567 (Rheumatology 2023;62:2534) HUMAN_CLINICAL
AMP kidney immune-cell landscape scRNA-seq Nature Immunology 2019 (PMID:31209404-adjacent) HUMAN_CLINICAL / molecular
LN race/ethnicity prevalence disparities ScienceDirect S0027968422000864; PMC11815449 HUMAN_CLINICAL (epidemiology)
Preeclampsia risk in LN pregnancy PMC8120629 HUMAN_CLINICAL
ISN/RPS 2018 classification revision PMID:33682052 HUMAN_CLINICAL
Pediatric LN ESRD progression timeline PMC11985274 HUMAN_CLINICAL
NZM2410 podocyte nephrin loss PLOS ONE PMC3805607 MODEL_ORGANISM
CAR-T CD19 durable remission in LN PMID:40446794 HUMAN_CLINICAL

Notes on Gaps for Curators

  1. Protective genetic/environmental factors specific to LN (vs. general SLE) were not well-represented in available literature — flag as KNOWLEDGE_GAP.
  2. Veterinary/naturally-occurring LN in other species is sparse; no OMIA-indexed entry surfaced.
  3. cGAS-STING pathway mechanistic detail specific to LN kidney tissue (vs. TREX1-driven SLE broadly) merits a dedicated follow-up search before finalizing pathway-level pathophysiology nodes.
  4. IFN-α's causal role in MRL/lpr is explicitly described in the literature as controversial — a strong candidate for a HUMAN_MODEL_MISMATCH discussion node rather than treating murine IFN data as directly confirmatory of human mechanism.

Sources